Modulating antibody dependent cellular phagocytosis

By modulating the amounts of terminal β-galactose, core-fucose, and high mannose species in IgG1 antibodies, the methods address the lack of understanding in ADCP activity, achieving targeted ADCP activity levels for enhanced therapeutic efficacy.

JP2024161535AInactive Publication Date: 2024-11-19AMGEN INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024138465
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-06-05
Filing Date
2024-08-20
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The influence of various glycans, such as β-galactose, core-fucose, and high mannose, on the antibody-dependent cellular phagocytosis (ADCP) activity of IgG1 antibodies like trastuzumab and rituximab is not fully understood, and critical quality attributes that predict and monitor ADCP activity during production are not well established.

Method used

Methods are developed to modulate ADCP activity by adjusting the amounts of terminal β-galactose, core-fucose, and high mannose species in IgG1 antibodies, including trastuzumab and rituximab, through glycan enrichment, removal, or remodeling, to achieve desired ADCP activity levels.

Benefits of technology

The methods allow for precise control of ADCP activity, increasing or decreasing it by specific percentages, thereby enhancing or reducing the antibody's efficacy in phagocytic processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161535000001_ABST
    Figure 2024161535000001_ABST
Patent Text Reader

Abstract

To provide methods of modulating Antibody Dependent Cellular Phagocytosis (ADCP) activity of therapeutic IgG1 monoclonal antibodies within an appropriate limit, range, or distribution.SOLUTION: In exemplary embodiments, the methods comprise modulating the amount of (a) galactosylated glycans of antibodies, (b) afucosylated glycans of the antibodies, (c) high mannose glycans of the antibodies, or (d) a combination thereof, to modulate ADCP activity of the antibodies.SELECTED DRAWING: Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to the modulation of antibody-dependent cellular phagocytosis (ADCP) effector functions of IgG1 antibodies, including trastuzumab and rituximab.

[0002] Incorporation by reference of electronic submissions The computer readable nucleotide / amino acid sequence listing submitted in computer readable format (CRF) contemporaneously with the present specification is incorporated by reference in its entirety, and is as follows: A 20 kilobyte ASCII (Text) file named A-2236-US-PSP_SeqlistingFinal.txt, created on June 5, 2018. [Background technology]

[0003] Throughout the development and manufacturing process of therapeutic monoclonal antibodies, it is essential to properly design and monitor the critical quality attributes that result in the desired safety and efficacy of the product. Critical quality attributes (CQAs) are defined as "physical, chemical, biological or microbiological properties or characteristics that should be within appropriate limits, ranges or distributions to ensure the required product quality." Many important therapeutic monoclonal antibodies are of the IgG1 subclass and therefore have the potential for Fc-mediated effector function activity, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) or complement-dependent cytotoxicity (CDC). See, for example, Jiang, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nature reviews Drug discovery 2011;10:101-11. Over the past approximately 15 years, much research has been conducted on the quality attributes that affect the potential for effector functions. It is well established that specific glycan structures associated with the conserved biantennary glycan in the Fc-CH2 domain can strongly influence interactions with FcγRs that mediate ADCC and ADCP, as well as C1q binding, the initial binding event leading to CDC (see Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 2015;25:1325-34).For example, structural, functional and binding studies have shown that core fucose has a profound effect on FcγRIIIa binding affinity, resulting in substantial changes in ADCC activity (see Okazaki A, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. Journal of molecular biology 2004;336:1239-49; Ferrara C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proceedings of the National Academy of Sciences of the United States of America 2011;108:12669-74). More recently, it has been shown that high mannose and β-galactose levels can also affect the regulation of ADCC activity, albeit to a much smaller and less predictable extent than core fucose (Thomann M, et al. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Molecular immunology 2016;73:69-75). Similarly, galactose has been shown to affect CDC by participating in C1q binding (Hodoniczky J, et al. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnology progress 2005;21:1644-52).Many of these observations have been made possible by glycoengineering processes that use engineered host cell lines to generate test materials that produce nonfucosylated or bisecting biantennary glycan structures of recombinant monoclonal antibodies (Shinkawa T, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. The Journal of biological chemistry 2003;278:3466-73; Umana P, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature biotechnology 1999;17:176-80). More recently, glycan-modifying enzymes and affinity enrichment chromatography columns have been used to generate well-focused distributions of specific substructures that can be characterized in effector function assays. This approach has been effectively deployed in ADCC studies (see, for example, Thomann M, et al. Molecular immunology 2016;73:69-75). Monitoring and control of glycan species that affect effector function activity is also central to biosimilar and follow-on drug development, presenting important properties and relevant activities for which strict similarity criteria must be applied.Recent examples where innovators have shown substantial drift in effector function-related properties have impacted efforts to develop biosimilar candidates (see Kim S, et al. Drifts in ADCC-related quality attributes of Herceptin(R): Impact on development of a trastuzumab biosimilar. mAbs 2017;9:704-14).

[0004] The contribution of ADCP in the efficacy of therapeutic antibodies is not fully understood, nor are the quality attributes that affect ADCP activity. The critical quality attributes that are most influential and predictive of ADCP activity and therefore most suitable to monitor during the manufacture of IgG1 antibodies have not been well established. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Jiang,et al.Advances in the assessment and control of the effector functions of therapeutic antibodies.Nature reviews Drug discovery 2011;10:101-11 [Non-Patent Document 2] Reusch D,Tejada ML.Fc glycans of therapeutic antibodies as critical quality attributes.Glycobiology 2015;25:1325-34 [Non-Patent Document 3] Okazaki A, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. Journal of molecular biology 2004;336:1239-49 [Non-Patent Document 4] Ferrara C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proceedings of the National Academy of Sciences of the United States of America 2011;108:12669-74 [Non-Patent Document 5] Thomann M, et al. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Molecular immunology 2016;73:69-75 [Non-Patent Document 6] Hodoniczky J, et al. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnology progress 2005;21:1644-52 [Non-Patent Document 7] Shinkawa T, et al.The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.The Journal of biological chemistry 2003;278:3466-73 [Non-Patent Document 8] Umana P,et al.Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.Nature biotechnology 1999;17:176-80 [Non-Patent Document 9] Thomann M,et al.Molecular immunology 2016;73:69-75 [Non-Patent Document 10] Kim S, et al.Drifts in ADCC-related quality attributes of Herceptin(R):Impact on development of a trastuzumab biosimilar.mAbs 2017;9:704-14 Summary of the Invention [Means for solving the problem]

[0006] The present disclosure aims to elucidate the effect of various glycans (e.g., including β-galactose, core-fucose and / or high mannose) on the ADCP activity of IgG1 antibodies, including trastuzumab or rituximab. In some embodiments, the present disclosure provides methods of modulating (i.e., increasing or decreasing) the ADCP activity of IgG1 antibodies (including methods of increasing or decreasing the ADCP activity of trastuzumab or rituximab) by increasing or decreasing glycan species (e.g., including enrichment, increase, removal and / or remodeling of β-galactose, core-fucose and / or high mannose species). The present disclosure also provides anti-IgG1 antibodies with increased or decreased ADCP activity, as well as methods for matching the ADCP activity of a second IgG1 antibody (including trastuzumab or rituximab) to that of a reference antibody by modulating (i.e., increasing or decreasing) the ADCP activity of the second IgG1 antibody by increasing or decreasing glycan species (including, for example, enriching, increasing, removing and / or remodeling β-galactose, core-fucose and / or high mannose species). Cell culture methods useful for modulating (i.e., increasing or decreasing) the ADCP activity of an IgG1 antibody (including increasing or decreasing the ADCP activity of trastuzumab or rituximab) by increasing or decreasing glycan species (including, for example, enriching, increasing, removing and / or remodeling β-galactose, core-fucose and / or high mannose species) are also disclosed.

[0007] In one aspect, the disclosure provides a method of modulating antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab comprising increasing or decreasing the amount of terminal β-galactose in an antibody, or increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of an antibody.

[0008] In another embodiment, the disclosure provides a method of increasing ADCP activity of trastuzumab comprising increasing the amount of terminal β-galactose in an antibody, or increasing the amount of G1, G1a, G1b and / or G2 galactosylated species of an antibody. In an exemplary embodiment, about a 1 percent increase in β-galactose increases ADCP activity by about 2.5, about 2.8, about 2.88, or about 3 percent.

[0009] In a further aspect, the disclosure provides a method of decreasing ADCP activity of trastuzumab comprising decreasing the amount of terminal β-galactose in the antibody or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody. In particular examples, about a 1 percent decrease in β-galactose decreases ADCP activity by about 2.5, about 2.8, about 2.88, or about 3 percent.

[0010] In a further aspect, the disclosure provides a method of matching the ADCP activity of a reference trastuzumab antibody comprising: (1) determining the ADCP activity of a reference trastuzumab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody; and (3) altering the ADCP activity of the second antibody by increasing or decreasing the amount of terminal β-galactose in the second antibody or increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the second antibody; wherein the ADCP activity of the second antibody after increasing or decreasing the amount of terminal β-galactose or increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody. In illustrative examples, the ADCP activity of a second antibody is increased by increasing the amount of terminal β-galactose in the second antibody or by increasing the amount of G1, G1a, G1b and / or G2 galactosylated species in the second antibody, and the ADCP activity of the second antibody after increasing the ADCP activity is the same as that of the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody. Optionally, the ADCP activity of the second antibody is reduced by decreasing the amount of terminal β-galactose in the second antibody or by decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species in the second antibody, such that the ADCP activity of the second antibody after reducing the ADCP activity is the same as the reference antibody or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some embodiments, step 1 ("determining the ADCP activity of a reference trastuzumab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody") and / or step 3 ("altering the ADCP activity of the second antibody...").In other embodiments, step 2 occurs before, after, or simultaneously with step 1 and / or step 3.

[0011] The disclosure also provides a method of engineering a particular target ADCP activity of a trastuzumab antibody, comprising: (1) determining an ADCP activity of a trastuzumab antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the antibody by increasing or decreasing the amount of terminal β-galactose in the antibody, or by increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of terminal β-galactose, or after increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species, is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some embodiments, step 1 ("determining the ADCP activity of a trastuzumab antibody") occurs before, after, or simultaneously with step 2 ("determining a target ADCP activity") and / or step 3 ("altering the ADCP activity of the antibody..."). In some embodiments, step 2 ("determining a target ADCP activity") occurs before, after, or simultaneously with step 1 ("determining the ADCP activity of a trastuzumab antibody") and / or step 3 ("altering the ADCP activity of the antibody...").

[0012] The present disclosure further provides a method of modulating the ADCP activity of trastuzumab or rituximab, comprising increasing or decreasing the amount of core fucose in the antibody, or increasing or decreasing the amount of non-fucosylated species of the antibody. The present disclosure further provides a method of increasing the ADCP activity of trastuzumab, comprising decreasing the amount of core fucose in the antibody, or increasing the amount of non-fucosylated species of the antibody. Optionally, about a 1 percent decrease in core fucose increases the ADCP activity of the trastuzumab antibody by about 0.5, about 0.56, about 0.6, or about 1 percent.

[0013] The present disclosure further provides a method of increasing the ADCP activity of rituximab comprising increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody, in some examples, an increase of about 1 percent in core fucose increases the ADCP activity of rituximab by about 0.5, about 0.7, about 0.75, about 0.8, or about 1 percent.

[0014] The present disclosure provides methods for decreasing the ADCP activity of trastuzumab, comprising increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody. In certain embodiments, an increase in core fucose of about 1 percent decreases the ADCP activity of the trastuzumab antibody by about 0.5, about 0.56, about 0.6, or about 1 percent.

[0015] The disclosure also provides a method of decreasing the ADCP activity of rituximab comprising decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species of the antibody. Optionally, about a 1 percent decrease in core fucose decreases the ADCP activity of rituximab by about 0.5, about 0.7, about 0.75, about 0.8, or about 1 percent.

[0016] The present disclosure also provides a method for matching ADCP activity of an IgG1 antibody, comprising the steps of: (1) determining the ADCP activity of a reference IgG1 antibody; (2) determining the ADCP activity of a second IgG1 antibody having the same sequence as the reference IgG1 antibody; and (3) altering the ADCP activity of the second IgG1 antibody by increasing or decreasing the amount of core fucose in the second antibody or increasing or decreasing the amount of non-fucosylated species of the second antibody; wherein the ADCP activity of the second antibody after increasing or decreasing the amount of core fucose or increasing or decreasing the amount of non-fucosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody. In a particular example, the reference antibody and the second IgG1 antibody are trastuzumab, and (a) the ADCP activity of the second antibody is increased by decreasing the amount of core fucose of the second antibody or increasing the amount of non-fucosylated species of the second antibody; or (b) the ADCP activity of the second trastuzumab antibody is decreased by increasing the amount of core fucose of the second antibody or decreasing the amount of non-fucosylated species of the second antibody. Alternatively, the reference antibody and the second IgG1 antibody are rituximab, and (a) the ADCP activity of the second rituximab antibody is increased by increasing the amount of core fucose of the second antibody or decreasing the amount of non-fucosylated species of the second antibody; or (b) the ADCP activity of the second rituximab antibody is decreased by decreasing the amount of core fucose of the second antibody or increasing the amount of non-fucosylated species of the second antibody. In some embodiments, step 1 ("determining the ADCP activity of a reference IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a second IgG1 antibody having the same sequence as the reference IgG1 antibody") and / or step 3 ("altering the ADCP activity of the second IgG1 antibody..."). In some embodiments, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0017] The disclosure also provides a method for manipulating a particular target ADCP activity of a trastuzumab antibody, comprising: (1) determining the ADCP activity of the trastuzumab antibody; (2) determining the target ADCP activity; and (3) altering the ADCP activity of the trastuzumab antibody by increasing or decreasing the amount of core fucose in the antibody or increasing or decreasing the amount of non-fucosylated species of the antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of core fucose or increasing or decreasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some embodiments, step 1 ("determining the ADCP activity of a trastuzumab antibody") occurs before, after, or simultaneously with step 2 ("determining a target ADCP activity") and / or step 3 ("altering the ADCP activity of a trastuzumab antibody..."). In some embodiments, step 2 ("determining a target ADCP activity") occurs before, after, or simultaneously with step 1 ("determining the ADCP activity of a trastuzumab antibody") and / or step 3 ("altering the ADCP activity of a trastuzumab antibody...").

[0018] The disclosure further provides a method of engineering a particular target ADCP activity of a rituximab antibody, comprising: (1) determining an ADCP activity of the rituximab antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the rituximab antibody by increasing or decreasing the amount of core fucose in the rituximab antibody or by increasing or decreasing the amount of non-fucosylated species of the rituximab antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of core fucose or increasing or decreasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some embodiments, step 1 ("determining the ADCP activity of a rituximab antibody") occurs before, after, or simultaneously with step 2 ("determining a target ADCP activity") and / or step 3 ("altering the ADCP activity of a rituximab antibody..."). In some embodiments, step 2 ("determining a target ADCP activity") occurs before, after, or simultaneously with step 1 ("determining the ADCP activity of a rituximab antibody") and / or step 3 ("altering the ADCP activity of a rituximab antibody...").

[0019] The disclosure also provides a method of modulating ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising increasing or decreasing the amount of high mannose in the antibody, or increasing or decreasing the amount of M5 high mannose species of the antibody.

[0020] The disclosure also provides a method of increasing ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising decreasing the amount of high mannose in the antibody or decreasing the amount of M5 high mannose species in the antibody. In some embodiments, about a 1 percent decrease in high mannose increases ADCP activity by about 1, about 1.2, about 1.31, about 1.5, about 1.7, about 2, about 2.11, or about 2.5 percent.

[0021] The present disclosure provides a method of decreasing ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising increasing the amount of high mannose in the antibody or increasing the amount of M5 high mannose species of the antibody. In some embodiments, about a 1 percent increase in high mannose decreases ADCP activity by about 1, about 1.2, about 1.31, about 1.5, about 1.7, about 2, about 2.11, or about 2.5 percent.

[0022] Also provided is a method of matching the ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising: (1) determining the ADCP activity of a reference IgG1 antibody; (2) determining the ADCP activity of a second IgG1 antibody that has the same sequence as the reference IgG1 antibody; and (3) altering the ADCP activity of the second IgG1 antibody by increasing or decreasing the amount of high mannose in the second antibody or increasing or decreasing the amount of M5 high mannose species of the second antibody; wherein the ADCP activity of the second antibody after increasing or decreasing the amount of high mannose or after increasing or decreasing the amount of M5 high mannose species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some aspects, the ADCP activity of the second IgG1 antibody is increased by decreasing the amount of high mannose in the second antibody or by decreasing the amount of M5 high mannose species in the second antibody. In an illustrative example, the ADCP activity of the second IgG1 antibody is decreased by increasing the amount of high mannose in the second antibody or by increasing the amount of M5 high mannose species in the second antibody. In some embodiments, step 1 ("determining the ADCP activity of a reference IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second IgG1 antibody") and / or step 3 ("altering the ADCP activity of a ... second IgG1 antibody"). In some embodiments, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0023] In another aspect, the disclosure provides a method of engineering a particular target ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising: (1) determining an ADCP activity of an IgG1 antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the IgG1 antibody by increasing or decreasing the amount of high mannose in the second antibody or increasing or decreasing the amount of M5 high mannose species in the second antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of high mannose or the amount of M5 high mannose species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some embodiments, step 1 ("determining the ADCP activity of an IgG1 antibody") occurs before, after, or simultaneously with step 2 ("determining a target ADCP activity") and / or step 3 ("altering the ADCP activity of an IgG1 antibody..."). In some embodiments, step 2 ("determining a target ADCP activity") occurs before, after, or simultaneously with step 1 ("determining the ADCP activity of an IgG1 antibody") and / or step 3 ("altering the ADCP activity of an IgG1 antibody...").

[0024] The present disclosure also provides a method of modulating ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising: (1) increasing or decreasing the amount of terminal β-galactose and / or the amount of G1, G1a, G1b and / or G2 galactosylated species in the antibody; (2) increasing the amount of core fucose and / or the amount of non-fucosylated species in the antibody; and / or (3) increasing the amount of high mannose or the amount of M5 high mannose species in the antibody. Additionally, a method of increasing ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising: (1) increasing the amount of terminal β-galactose or the amount of G1, G1a, G1b and / or G2 galactosylated species in the antibody; (2) decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species in the antibody; and / or (3) decreasing the amount of high mannose in the antibody or decreasing the amount of M5 high mannose species in the antibody, is provided. In other exemplary embodiments, the disclosure provides a method of decreasing ADCP activity of an IgG1 antibody (such as trastuzumab or rituximab), comprising: (1) decreasing the amount of terminal β-galactose or the amount of G1, G1a, G1b and / or G2 galactosylated species in the antibody; (2) increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species in the antibody; and / or (3) increasing the amount of high mannose or the amount of M5 high mannose species in the antibody.

[0025] In illustrative examples of the disclosed methods, (1) the amount of terminal β-galactose or the amount of G1, G1a, G1b and / or G2 galactosylated species; (2) the amount of core fucose or the amount of non-fucosylated species; and / or (3) the amount of high mannose or the amount of M5 high mannose species is increased or decreased by culturing cells expressing the antibody in a cell culture medium or under cell culture conditions that modulate the amount of one or more of these glycans (e.g., terminal β-galactose; G1, G1a, G1b and / or G2 galactosylated species; core fucose; non-fucosylated species; high mannose and / or M5 high mannose species). In some embodiments, the amount of these glycans (e.g., terminal β-galactose; G1, G1a, G1b, and / or G2 galactosylated species; core fucose; nonfucosylated species; high mannose and / or M5 high mannose species) is increased or decreased by chemical means or using enzymes, such as EndoS, Endo-S2, Endo-D, Endo-M, endoLL, α-fucosidase, β-(1-4)-galactosidase, Endo-H, β-1,4-galactosyltransferase, and / or PNGase F. In certain aspects, the amount of these glycans is adjusted by incubating the antibody with β-1,4-galactosyltransferase for about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 9 hours, or for a time ranging from about 10 minutes to about 9 hours.

[0026] The present disclosure also provides an antibody composition produced by any one of the methods of the present disclosure. In certain embodiments, the antibody has increased or decreased ADCP activity compared to a reference IgG1 antibody (which reference IgG1 antibody has the same antibody sequence as the IgG1 antibody having increased or decreased ADCP activity). In some examples, the antibody has about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, about 150%, about 175% or about 200%, or about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold or about 10-fold increased ADCP activity compared to the reference antibody, or about 0.5-fold to about 8-fold increased ADCP activity compared to the reference antibody. In some cases, the antibody has about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, about 150%, about 175%, or about 200%, or about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold decreased ADCP activity compared to a reference antibody, or about 0.5-fold to about 8-fold decreased ADCP activity compared to a reference antibody. In an exemplary embodiment, the IgG1 antibody is trastuzumab or rituximab comprising any one of the sequences listed in Tables 1 or 2.

[0027] The present disclosure further provides a pharmaceutical composition comprising any one of the antibody compositions described herein. [Brief description of the drawings]

[0028] [Figure 1A] FIG. 1A is an illustration of the three types of N-glycans (oligomannose, complex and hybrid) and the symbols commonly used for such saccharides. [Figure 1B]Figure 1B is a schematic diagram showing the major N-linked glycans found in human IgG at the N-glycosylation site asparagine (Asn) 297, with representative linkages of oligosaccharide structures. These glycans are typically composed of a heptasaccharide core and outer arms built by the variable addition of fucose, N-acetylglucosamine (GlcNAc), galactose, sialic acid (SA), and bisected N-GlcNAc. [Figure 1C] FIG. 1C is a diagram of the salvage and de novo pathways of fucose metabolism. In the salvage pathway, free L-fucose is converted to GDP-fucose, whereas in the de novo pathway, GDP-fucose is synthesized through three reactions catalyzed by GMD and FX. GDP-fucose is then transported from the cytosol to the lumen of the Golgi by GDP-Fuc transferase and transferred to acceptor oligosaccharides and proteins. The other reaction product, GDP, is converted by luminal nucleotide diphosphatase to guanosine 5-monophosphate (GMP) and inorganic phosphate (Pi). The former is exported to the cytosol (via an antiport system coupled to the transport of GDP-fucose), whereas the latter is assumed to leave the Golgi lumen via the Golgi anion channel, GOLAC. See, for example, Nordeen et al. 2000; Hirschberg et al. 2001. [Diagram 2] Figure 2 shows dose-response curves (smooth fit) of three different IgG1 mAbs targeting the HER2 (trastuzumab), TNFα, or CD20 (rituximab) cell surface antigens in an ADCP reporter gene assay, showing that the tested antibodies showed a range of activity in this ADCP assay: the anti-TNFα antibody showed virtually no response, the anti-CD20 antibody showed a very robust response, and the anti-HER2 antibody showed an intermediate response. [Figure 3A]Figures 3A-D are graphs showing linear and range evaluations for the anti-CD20 antibody rituximab (Figures 3A-B) and the anti-HER2 antibody trastuzumab (Figures 3C-D). Linear regression lines (equations shown) were fitted to plots showing the relationship between measured and known ADCP activity for each antibody (Figures 3A and 3C), and representative dose-response curves were shown for various activity levels in the correlated line graphs (Figures 3B and 3D). This data demonstrated the quantitative nature and range of the ADCP reporter gene assay and its suitability for evaluation of quality attributes that affect ADCP activity. [Figure 3B] Figures 3A-D are graphs showing linear and range evaluations for the anti-CD20 antibody rituximab (Figures 3A-B) and the anti-HER2 antibody trastuzumab (Figures 3C-D). Linear regression lines (equations shown) were fitted to plots showing the relationship between measured and known ADCP activity for each antibody (Figures 3A and 3C), and representative dose-response curves were shown for various activity levels in the correlated line graphs (Figures 3B and 3D). This data demonstrated the quantitative nature and range of the ADCP reporter gene assay and its suitability for evaluation of quality attributes that affect ADCP activity. [Figure 3C] Figures 3A-D are graphs showing linear and range evaluations for the anti-CD20 antibody rituximab (Figures 3A-B) and the anti-HER2 antibody trastuzumab (Figures 3C-D). Linear regression lines (equations shown) were fitted to plots showing the relationship between measured and known ADCP activity for each antibody (Figures 3A and 3C), and representative dose-response curves were shown for various activity levels in the correlated line graphs (Figures 3B and 3D). This data demonstrated the quantitative nature and range of the ADCP reporter gene assay and its suitability for evaluation of quality attributes that affect ADCP activity. [Figure 3D]Figures 3A-D are graphs showing linear and range evaluations for the anti-CD20 antibody rituximab (Figures 3A-B) and the anti-HER2 antibody trastuzumab (Figures 3C-D). Linear regression lines (equations shown) were fitted to plots showing the relationship between measured and known ADCP activity for each antibody (Figures 3A and 3C), and representative dose-response curves were shown for various activity levels in the correlated line graphs (Figures 3B and 3D). This data demonstrated the quantitative nature and range of the ADCP reporter gene assay and its suitability for evaluation of quality attributes that affect ADCP activity. [Figure 4] FIG. 4 summarizes the structures of the three major glycan species evaluated in the ADCP reporter gene assay, including nonfucosylated species (i.e., species lacking core fucose, including G0 or G1), high mannose species (including M5 species), or terminal β-galactose species (i.e., terminal β-galactose, including G1F or G2F). [Diagram 5] FIG. 5 is a representative ADCP dose-response curve for an anti-HER2 antibody (trastuzumab) with a wide range of β-galactose levels, showing that higher levels of β-galactose generally result in higher ADCP activity. [Figure 6] 6 is a line graph showing the correlation between the ADCP activity of the anti-HER2 antibody trastuzumab and β-galactose levels. The relative effect of β-galactose on the ADCP activity of trastuzumab was calculated to be 2.88. [Figure 7] FIG. 7 is a bar graph reporting the relative ADCP activity of an anti-CD20 antibody (rituximab) across two broad ranges of β-galactose levels (0% and 81% β-galactose). [Figure 8] FIG. 8 is a line graph reporting the correlation between FcγRIIa binding of the anti-HER2 antibody trastuzumab and β-galactose levels as measured by an FcγRIIa binding assay using the AlphaLISA format. [Figure 9A]Figures 9A-B are bar graphs reporting the relative target binding activity of selected β-galactose samples as indicated, normalized to the activity of the minimum β-lactose level, for CD20 / rituximab (Figure 9A) and HER2 / trastuzumab (Figure 9B) antibodies. These results indicate that the observed differences in relative ADCP activity are due to differences in FcγRIIa binding and not due to unexpected changes in cell surface target binding. [Figure 9B] Figures 9A-B are bar graphs reporting the relative target binding activity of selected β-galactose samples as indicated, normalized to the activity of the minimum β-lactose level, for CD20 / rituximab (Figure 9A) and HER2 / trastuzumab (Figure 9B) antibodies. These results indicate that the observed differences in relative ADCP activity are due to differences in FcγRIIa binding and not due to unexpected changes in cell surface target binding. [Figure 10A] Figures 10A-B are line graphs reporting the correlation between ADCP activity and defucosylation for the anti-HER2 antibody trastuzumab (Figure 10A) and the anti-CD20 antibody rituximab (Figure 10B). The data show a linear increase in ADCP activity with increasing defucosylation of trastuzumab (response factor 0.56). Rituximab showed a small linear decrease in ADCP activity with increasing defucosylation. [Figure 10B] Figures 10A-B are line graphs reporting the correlation between ADCP activity and defucosylation for the anti-HER2 antibody trastuzumab (Figure 10A) and the anti-CD20 antibody rituximab (Figure 10B). The data show a linear increase in ADCP activity with increasing defucosylation of trastuzumab (response factor 0.56). Rituximab showed a small linear decrease in ADCP activity with increasing defucosylation. [Figure 11A]Figures 11A-B are line graphs reporting the correlation between β-galactose and ADCP activity (Figure 11A) or β-galactose and FcγRIIa binding (Figure 11B) of trastuzumab for samples with a fixed high mannose content and for samples containing a range of high mannose. The data suggest that increasing high mannose levels reduces ADCP activity and FcγRIIa binding of trastuzumab. [Figure 11B] Figures 11A-B are line graphs reporting the correlation between β-galactose and ADCP activity (Figure 11A) or β-galactose and FcγRIIa binding (Figure 11B) of trastuzumab for samples with a fixed high mannose content and for samples containing a range of high mannose. The data suggest that increasing high mannose levels reduces ADCP activity and FcγRIIa binding of trastuzumab. [Figure 12A] Figures 12A-B are line graphs reporting the correlation between high mannose and ADCP activity (Figure 12A) or FcγRIIa binding (Figure 12B) of the rituximab anti-CD20 antibody. The data suggest that increasing high mannose levels reduces the ADCP activity and FcγRIIa binding of rituximab. [Figure 12B] Figures 12A-B are line graphs reporting the correlation between high mannose and ADCP activity (Figure 12A) or FcγRIIa binding (Figure 12B) of the rituximab anti-CD20 antibody. The data suggest that increasing high mannose levels reduces the ADCP activity and FcγRIIa binding of rituximab. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] In order that this disclosure may be more readily understood, certain terms are first defined. Further definitions are provided throughout the detailed description.

[0030] The terms "a", "an" and "the" and similar referents with respect to the description of this disclosure (especially with respect to the claims below) as used herein should be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising", "having", "including", and "containing" should be construed as open-ended terms (i.e., meaning "including, but not limited to" and allowing for the presence of one or more features or components), unless otherwise specified. The terms "a" (or "an"), as well as "one or more" and "at least one" can be used interchangeably herein. Furthermore, "and / or" as used herein should be construed as a specific disclosure of each of two specific features or components (with or without the other feature or component). Thus, the term "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).

[0031] The term "about" as used in connection with numerical values ​​throughout the specification and claims indicates an interval of accuracy well known and accepted by those skilled in the art. Typically, such interval of accuracy is ±10%.

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press, The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press, and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure. In general, the nomenclature used in connection with cell and tissue culture, molecular biology, immunology, protein glycosylation, antibody production and antibody purification described herein, and the techniques thereof, are well known and commonly used in the art. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, tissue culture and transformation, protein purification, antibody production, and the like. Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The following procedures and techniques can be generally performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout the specification. See, e.g., Sambrook et al., 2001, Molecular Cloning: A Laboratory Manuel, 3rd ed., Cold Spring Harbor Laboratory Press, cold Spring Harbor, NY, which is incorporated herein by reference for any purpose.

[0033] Units, prefixes and symbols are shown in the format accepted by the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not intended to limit the various aspects or aspects of the disclosure, which may be had by reference to the entire specification.

[0034] Post-translational glycosylation Many secreted proteins are post-translationally glycosylated, a process by which sugar moieties (e.g., glycans, sugars) are covalently attached to specific amino acids of proteins. In eukaryotic cells, two types of glycosylation reactions occur: (1) N-linked glycosylation, in which the glycan is linked to an asparagine at the recognition sequence Asn-X-Thr / Ser (where "X" is any amino acid except proline), and (2) O-linked glycosylation, in which the glycan is linked to a serine or threonine. Regardless of the type of glycosylation (N-linked or O-linked), there is a wide range of glycan structures attached to each site (O or N), resulting in microheterogeneity of protein glycoforms.

[0035] All N-glycans have a common core sugar sequence: Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1-Asn-X-Ser / Thr (Man3GlcNAc2Asn) and are classified into one of three types: (A) high mannose (HM) or oligomannose (OM) types, consisting of two N-acetylglucosamine (GalNAc) moieties and multiple (e.g., 5, 6, 7, 8, or 9) mannose (Man) residues, (B) complex types, containing three or more GlcNAc moieties and any number of other sugar types, or (C) hybrid types, containing a Man residue on one branch and a GlcNAc at the base of the complex branch. Figure 1A (Stanley et al., Chapter 8: N-Glycans, Essentials of Glycobiology, 2 nded., Cold Spring Harbor Laboratory Press; 2009) shows three types of N-glycans:

[0036] N-linked glycans typically contain one or more of the following monosaccharides: galactose (Gal), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), mannose (Man), N0-acetylneuraminic acid (Neu5Ac), and fucose (Fuc). Commonly used symbols for these sugars are shown in Figure 1A.

[0037] N-linked glycosylation is initiated in the endoplasmic reticulum (ER) and a complex series of reactions results in the attachment of a core glycan structure, essentially made up of two GlcNAc and three Man residues. The glycan complex formed in the ER is modified by the action of enzymes in the Golgi apparatus. If the sugar is relatively inaccessible to the enzymes, it generally remains in its original HM form. If the sugar is accessible to the enzymes, many of the Man residues are cleaved off and the sugar is further modified, resulting in complex N-glycan structures. For example, mannosidase-1, located in the cis-Golgi, can cleave or hydrolyze HM glycans, while fucosyltransferase FUT-8, located in the medial-Golgi, fucosylates the glycans (Hanrue Imai-Nishiya (2007), BMC Biotechnology, 7:84).

[0038] Thus, the sugar composition and structural configuration of a glycan structure varies depending, inter alia, on the glycosylation machinery in the ER and Golgi apparatus, the accessibility of the glycan structure to the enzymes of that machinery, the order of action of each enzyme, and the stage at which the protein is released from the glycosylation machinery.

[0039] Controlling glycan structure attached to the Fc domain is important in the recombinant production of therapeutic monoclonal antibodies, as it influences the interaction with FcγRs that mediate ADCC and ADCP, as well as C1q binding, the initial binding event that leads to CDC.

[0040] The present disclosure elucidates the effect of various glycans (e.g., containing β-galactose, core-fucose and / or high mannose) on the ADCP activity of IgG1 antibodies, including trastuzumab or rituximab. Thus, the present disclosure provides a method for modulating the ADCP activity of an antibody or a composition comprising the same (antibody composition). In an exemplary embodiment, the method comprises modulating the amount of (a) a galactosylated glycan of the antibody, (b) a non-fucosylated glycan of the antibody, (c) a high mannose glycan of the antibody, or (d) a combination thereof. Without being bound to a particular theory, it is believed that the method of the present disclosure provides a means to tailor-made compositions comprising specific amounts of specific glycoforms of a given antibody that exhibit a target level of ADCP activity.

[0041] The term "antibody-dependent cellular phagocytosis" or "ADCP" refers to a mechanism by which antibody-opsonized target cells activate FcγRs on the surface of cells of the immune system (including, for example, macrophages and / or neutrophils) to induce phagocytosis, resulting in internalization and degradation of the target cell via acidification of the phagosome. ADCP generally requires a two-step mechanism: (1) binding of an antibody to an antigen or target on a cell, and (2) binding of the antibody to a receptor (Fc receptor) on macrophages or other phagocytes to induce internalization, degradation and / or destruction of the antibody-bound cell. See, e.g., Guel N and Egmond M. Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer. Cancer Res December 1 2015(75)(23)5008-5013.

[0042] The term "FcγR" or "Fc-gamma receptor" refers to a protein belonging to the IgG superfamily that is involved in inducing phagocytosis of opsonized cells or microorganisms. See, e.g., Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB Journal. 5(12):2684-90 (1991). Members of the Fc-gamma receptor family include FcγRI (CD64), FcγRIIA (CD32), FcγRIIB (CD32), FcγRIIIA (CD16a), and FcγRIIIB (CD16b). The sequences of FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, and FcγRIIIB can be found in many sequence databases, for example the Uniprot database (www.uniprot.org) under accession numbers P12314 (FCGR1_HUMAN), P12318 (FCG2A_HUMAN), P31994 (FCG2B_HUMAN), P08637 (FCG3A_HUMAN), and P08637 (FCG3A_HUMAN), respectively.

[0043] The term "ADCP activity" refers to the degree to which phagocytosis, which leads to internalization and degradation of the target cell via acidification of the phagosome, is activated or stimulated by a two-step mechanism of (1) binding of an antibody to an antigen or target on a cell, and (2) binding of the antibody to a receptor (Fc receptor) on a macrophage or other phagocyte to induce internalization, degradation, and / or destruction of the antibody-bound cell. The phrase "ADCP activity of an antibody" refers to the ability of an antibody to induce ADCP.

[0044] Methods for measuring or determining ADCP activity of antibodies, including commercially available assays and kits, are described, for example, in Richards, JO et al. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 2008;7,2517-27; Ackerman et.al, A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. Journal of Immunological Methods 366(2011)8-19; Chung S,et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. mAbs 2012;4:326-40; Herbrand U. Antibody-dependent cellular phagocytosis:the mechanism of action that gets no respect-A discussion about improving bioassay reproducibility. BioProcess J, 2016;15(1):26-9, ADCP Bioassays (Promega, catalog number G9901 or G9991), and ADCP Bioassay (BPS Bioscience, catalog number 60540 or 60541), all of which are incorporated herein by reference for all purposes. The term "ADCP assay" or "FcγR reporter gene assay" refers to an assay, kit, or method useful for determining the ADCP activity of an antibody.

[0045] Exemplary methods for measuring or determining the ADCP activity of an antibody in the methods described herein include the ADCP assay described in the Examples or the ADCP reporter assay commercially available from Promega (catalog number G9901 or G9991). In some embodiments, ADCP activity is measured or determined using a reporter gene assay, for example, an FcγR reporter gene assay that includes one or more of the following: Jurkat cells expressing FcγR receptors (including, for example, FcγRIIa), nuclear factor of activated T cells (NFAT) response element, and luciferase or other reporter gene or reporter product. In an exemplary aspect, ADCP activity is measured using cells expressing FcγRIIa on the cell surface, for example, Jurkat T cells, and a reporter gene assay that includes a reporter gene linked to NFAT activity.

[0046] Regulation of ADCP activity The term "modulate" or "modulating" means to change by increasing or decreasing. Thus, the term "modulate" as used herein in phrases such as "modulate antibody-dependent cellular phagocytosis" is intended to include increasing antibody-dependent cellular phagocytosis or decreasing antibody-dependent cellular phagocytosis. Also, the term "modulate" as used in phrases such as "modulate the amount of galactosylated glycans, non-fucosylated glycans, high mannose glycans, or combinations thereof" is intended to include increasing the amount of the glycans or decreasing the amount of the glycans.

[0047] Thus, in exemplary embodiments, the presently disclosed methods represent methods of increasing the ADCP activity of an antibody or a composition comprising same. In exemplary aspects, the disclosed methods increase the ADCP activity of an antibody or a composition comprising same to any degree or level as compared to a control or reference antibody. In exemplary examples, the increase provided by the disclosed methods is an increase of at least or about 1% to about 100% as compared to a control or reference antibody (e.g., at least or about 1% increase, at least or about 2% increase, at least or about 3% increase, at least or about 4% increase, at least or about 5% increase, at least or about 6% increase, at least or about 7% increase, at least or about 8% increase, at least or about 9% increase, at least or about 9.5% increase, at least or about 9.8% increase, at least or about 10% increase, at least or about 15% increase, at least or about 20% increase, at least or about 2 ... at least or about a 20% increase, at least or about a 25% increase, at least or about a 30% increase, at least or about a 35% increase, at least or about a 40% increase, at least or about a 45% increase, at least or about a 50% increase, at least or about a 55% increase, at least or about a 60% increase, at least or about a 65% increase, at least or about a 70% increase, at least or about a 75% increase, at least or about an 80% increase, at least or about an 85% increase, at least or about a 90% increase, at least or about a 95% increase, at least or about a 100% increase). In exemplary embodiments, the increase provided by the disclosed method is greater than 100%, for example, at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is increased by at least about 1.5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is increased by at least about 2-fold compared to a control or reference antibody.In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by at least about 3-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by at least about 4-fold or about 5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0048] In alternative embodiments, the methods of the present disclosure refer to methods of decreasing the ADCP activity of an antibody or a composition comprising the same. In some aspects, the methods of the present disclosure decrease the level of ADCP activity of an antibody or a composition comprising the same to any degree or level, as compared to a control or reference antibody. The decrease provided by the methods of the present disclosure can be a decrease of at least or about 1% to about 100% (e.g., at least or about 1% decrease, at least or about 2% decrease, at least or about 3% decrease, at least or about 4% decrease, at least or about 5% decrease, at least or about 6% decrease, at least or about 7% decrease, at least or about 8% decrease, at least or about 9% decrease, at least or about 9.5% decrease, at least or about 9.8% decrease, at least or about 10% decrease, at least or about 15% decrease, at least or about 20% decrease, at least or about 2 ... at least or about a 20% reduction, at least or about a 25% reduction, at least or about a 30% reduction, at least or about a 35% reduction, at least or about a 40% reduction, at least or about a 45% reduction, at least or about a 50% reduction, at least or about a 55% reduction, at least or about a 60% reduction, at least or about a 65% reduction, at least or about a 70% reduction, at least or about a 75% reduction, at least or about a 80% reduction, at least or about a 85% reduction, at least or about a 90% reduction, at least or about a 95% reduction, at least or about a 100% reduction). In exemplary embodiments, the reduction provided by the methods of the present disclosure is greater than about 100%, for example, at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to the level of a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is reduced by at least about 1.5-fold compared to the control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is reduced by at least about 2-fold compared to the control or reference antibody.In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by at least about 3-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by at least about 4-fold or at least about 5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0049] Glycan In an exemplary embodiment, the method disclosed herein comprises modulating the amount of glycans on an antibody, including (a) galactosylated glycans, (b) non-fucosylated glycans, (c) high mannose glycans, or (d) a combination thereof, to increase or decrease the ADCP activity of the antibody. In an exemplary embodiment, the method disclosed herein comprises modulating the amount of glycans attached to the Fc domain of the antibody, including (a) galactosylated glycans, (b) non-fucosylated glycans, (c) high mannose glycans, or (d) a combination thereof, to increase or decrease the ADCP activity of the antibody. In a further exemplary embodiment, the method disclosed herein comprises modulating the amount of glycans attached to Asn-297 of the Fc domain of the antibody, including (a) galactosylated glycans, (b) non-fucosylated glycans, (c) high mannose glycans, or (d) a combination thereof, to increase or decrease the ADCP activity of the antibody.

[0050] In an exemplary aspect, a method provided by the present disclosure relates to modulating an antibody composition, e.g., an IgG1 antibody composition (e.g., comprising trastuzumab or rituximab), in which a step is taken to achieve a desired, predetermined, or preselected level of glycoforms of the IgG1 antibody to achieve a desired, predetermined, or preselected level of ADCP activity. In an exemplary embodiment, the method comprises modulating (increasing or decreasing) the amount of (a) galactosylated glycans, (b) nonfucosylated glycans, (c) high mannose glycans, or (d) a combination thereof, of the IgG1 antibody to modulate (increase or decrease) ADCP activity induced or stimulated by the antibody composition. In an exemplary embodiment, the method comprises modulating (increasing or decreasing) the amount of glycoforms, e.g., (a) galactosylated glycoforms, (b) nonfucosylated glycoforms, (c) high mannose glycoforms, or (d) a combination thereof, to modulate (increase or decrease) ADCP activity induced or stimulated by the antibody composition. Without wishing to be bound by any particular theory, it is believed that the methods disclosed herein provide a means to engineer an antibody composition with a desired, predetermined, or target ADCP activity by modulating (i.e., increasing or decreasing) the amount of a particular glycoform of a given antibody. Thus, in some embodiments, the methods disclosed herein involve modulating the amount or proportion of (a) galactosylated glycans, (b) nonfucosylated glycans, (c) high mannose glycans, or (d) a combination thereof in an antibody composition to achieve a composition with a desired, predetermined, or target ADCP activity, and / or increased or decreased ADCP activity.

[0051] In alternative aspects, the methods disclosed herein include modulating the amount of terminal β-galactose, core fucose, or high mannose, or a combination thereof, attached to a particular IgG1 molecule (including, for example, trastuzumab or rituximab). For example, the methods can include increasing the amount of terminal β-galactose on trastuzumab (e.g., by effectively changing the glycan from a G0 species to a G1 or G2 species, or from a G1 species to a G2 species) to increase the ADCP activity of the trastuzumab antibody. Also, for example, the methods can include decreasing the amount of terminal β-galactose on trastuzumab (e.g., by effectively changing the glycan from a G2 species to a G1 or G0 species, or from a G1 species to a G0 species) to decrease the ADCP activity of the trastuzumab antibody. In another exemplary embodiment, the method may include decreasing the amount of core fucose or increasing the amount of non-fucosylated species in the trastuzumab antibody to increase ADCP activity. In another exemplary embodiment, the method may include increasing the amount of core fucose or decreasing the amount of non-fucosylated species in the rituximab antibody to increase ADCP activity of the antibody. In another exemplary embodiment, the method may include increasing the amount of core fucose or decreasing the amount of non-fucosylated species in the trastuzumab antibody to decrease ADCP activity. In another exemplary embodiment, the method may include decreasing the amount of core fucose or increasing the amount of non-fucosylated species in the rituximab antibody to decrease ADCP activity of the antibody. In a further exemplary embodiment, the method may include increasing the amount of high mannose or M5 high mannose on an IgG1 antibody (such as trastuzumab or rituximab) to decrease the ADCP activity of the antibody, or decreasing the amount of high mannose or M5 high mannose on an IgG1 antibody (such as trastuzumab or rituximab) to increase the ADCP activity of the antibody.

[0052] The terms "glycan", "glycans", "glycoform" or "glycoforms" refer to oligomers of monosaccharide species linked by various glycosidic bonds. Examples of monosaccharides commonly found in mammalian N-linked glycans include hexose (Hex), glucose (Glc), galactose (Gal), mannose (Man) and N-acetylglucosamine (GlcNAc). The major N-glycan species found on recombinant IgG1 antibodies include fucose, galactose, mannose, sialic acid and GlcNAc, as shown in FIG. 1B. Glycan oligosaccharide structures are attached to the N-glycosylation site at Asn-297 and generally consist of a heptasaccharide core with outer arms constructed by the variable addition of fucose, N-acetylglucosamine (GlcNAc), galactose, sialic acid (SA), and bisected N-GlcNAc. Each of the potential oligosaccharide structures can be abbreviated as follows: G0, G1 or G2 refer to a core GlcNAc and mannose oligosaccharide structure with 0, 1 or 2 terminal galactose molecules, respectively. G1 has two additional structures, abbreviated G1a and G1b, where G1a or G1b may indicate whether the terminal galactose group is attached to the 6-arm or 3-arm of the core structure. See FIG. 1B. If fucosylated (i.e., when a fucose group is attached to the core glycan structure), the G0, G1 (G1a / G1b) or G2 types can be abbreviated as G0F, G1F (G1aF / G1bF) or G2F. If sialic acid is present, these abbreviations include an "S", e.g., G2FS2 refers to a glycan with two galactose, fucose and two sialic acid groups. There may also be additional glycans linked to the IgG1 antibody, including high mannose (HM) structures formed by the incorporation of additional mannose groups, for example the high mannose species "M5" as shown in Figure 4. As used herein, the term "glycan" or "glycans" refers to any of the oligomers of monosaccharide species described herein, or any other oligomers of monosaccharide species linked to an antibody or IgG1 antibody.

[0053] "Terminal β-galactose", "galactosylated glycan" or "G1, G1a, G1b and / or G2 galactosylated species" refers to a glycan that comprises one or two galactose molecules linked to an IgG1 antibody at the N-glycosylation site (Asn-297) via an N-acetylglucosamine moiety that is linked to a core mannose structure. Exemplary glycans that comprise "terminal β-galactose", "galactosylated glycan" or "G1, G1a, G1b and / or G2 galactosylated species" are shown in FIG. 1B. In some embodiments, the G1, G1a, G1b and / or G2 galactosylated species may or may not comprise a core fucose.

[0054] The term "core fucose" or "fucosylated species" refers to a glycan comprising a fucose molecule (alpha 1-6) linked to an IgG1 antibody at the N-glycosylation site (Asn-297) via an N-acetylglucosamine moiety linked to a core mannose structure. Exemplary glycans comprising "core fucose" or "fucosylated species" are shown in FIG. 1B. In some embodiments, antibodies comprising core fucose and / or fucosylated species may or may not comprise other glycans comprising terminal β-galactose and / or high mannose.

[0055] The terms "nonfucosylated", "nonfucosylated glycan" or "nonfucosylated" refer to the removal or absence of core fucose on an antibody. Exemplary nonfucosylated antibody species are shown in FIG. 1B. In some embodiments, antibodies lacking core fucose may or may not include other glycans containing terminal β-galactose and / or high mannose. Nonfucosylated glycoforms include, but are not limited to, A1G0, A1G1a, A2G0, A2G1a, A2G1b, A2G2, and A1G1M5. See, e.g., Reusch and Tejada, Glycobiology 25(12):1325-1334 (2015).

[0056] The terms "high mannose", "high mannose glycan" or "HM" refer to a glycan containing more than three mannose molecules linked to an IgG1 antibody at the N-glycosylation site (Asn-297). Exemplary high mannose antibodies are shown in Figure 4, including the "M5 high mannose antibody species" which contains two additional mannose molecules. High mannose glycans encompass glycans containing 5, 6, 7, 8, or 9 mannose residues, abbreviated as Man5, Man6, Man7, Man8, and Man9, respectively.

[0057] The term "amount," when referring to the amount of a glycan (including, for example, (1) the amount of terminal β-galactose, (2) the amount of G1, G1a, G1b and / or G2 galactosylated species, (3) the amount of core fucose, (4) the amount of non-fucosylated species, (5) the amount of high mannose, and / or (6) the amount of M5 high mannose species), refers to the relative amount or proportion of a particular glycan compared to the total amount of glycan. For example, the amount of (1) terminal β-galactose, (2) G1, G1a, G1b and / or G2 galactosylated species, (3) core fucose, (4) non-fucosylated species, (5) high mannose, and / or (6) M5 high mannose species is presented as a percentage calculated by dividing the amount of terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, core fucose, non-fucosylated species, high mannose, or M5 high mannose species by the total amount of all glycans. Methods for measuring and determining the amount or relative proportion of glycans (e.g., including terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, core fucose, non-fucosylated species, high mannose, and / or M5 high mannose species) are well known in the art and include hydrophilic interaction liquid chromatography (HILIC) as described in the Examples. See also Pace et al., Characterizing the Effect of Multiple Fc Glycan Attributes on the Effector Functions and FccRIIIa Receptor Binding Activity of an IgG1 Antibody, Biotechnol. Prog., 2016, Vol. 32, No. 5 pages 1181-1192, and Shah, B. et al. LC-MS / MS Peptide Mapping with Automated Data Processing for Routine Profiling of N-Glycans in Immunoglobulins J. Am. Soc. Mass Spectrom. (2014) 25:999, each of which is incorporated by reference herein for all purposes. In some embodiments, the amount can be determined or calculated as a mole percent incorporation.

[0058] Regulation of glycan abundance As used herein, "modulate" means to change by decreasing or increasing, and thus, in exemplary embodiments, the methods disclosed herein include increasing and / or decreasing the amount of glycans of an antibody. In exemplary embodiments, the methods disclosed herein include increasing the glycans of an antibody (e.g., galactosylated glycans, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) to any degree or level compared to a control or reference antibody. In illustrative examples, the method includes increasing the glycans by at least or about 1% to about 100% (e.g., at least or about 1%, at least or about 2%, at least or about 3%, at least or about 4%, at least or about 5%, at least or about 6%, at least or about 7%, at least or about 8%, at least or about 9%, at least or about 9.5%, at least or about 9.8%, at least or about 10%, at least or about 15%, at least or about 20%, at least or about 25%, at least or about 30%, at least or about 35%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 55%, at least or about 60%, at least or about 65%, at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 100%) compared to a control or reference antibody. In exemplary embodiments, the method includes increasing the glycan by 100% or more, e.g., at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to a control or reference antibody. In exemplary embodiments, the method includes increasing the glycan by at least about 1.5-fold compared to a control or reference antibody.In an exemplary embodiment, the method includes increasing the glycan by at least about 2-fold compared to a control or reference antibody. In an exemplary embodiment, the method includes increasing the glycan by at least about 3-fold compared to a control or reference antibody. In an exemplary embodiment, the method includes increasing the glycan by at least about 4-fold or about 5-fold compared to a control or reference antibody. In an exemplary embodiment, the method includes increasing the glycan by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In an exemplary embodiment, the method includes increasing the glycan by at least an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0059] In exemplary aspects, the methods of the disclosure include reducing glycans of an antibody (e.g., galactosylated glycans, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) to any degree or level compared to a control or reference antibody. In illustrative examples, the method includes reducing glycans by at least or about 1% to about 100% (e.g., at least or about 1%, at least or about 2%, at least or about 3%, at least or about 4%, at least or about 5%, at least or about 6%, at least or about 7%, at least or about 8%, at least or about 9%, at least or about 9.5%, at least or about 9.8%, at least or about 10%, at least or about 15%, at least or about 20%, at least or about 25%, at least or about 30%, at least or about 35%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 55%, at least or about 60%, at least or about 65%, at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 100%) compared to a control or reference antibody. In exemplary embodiments, the method includes reducing glycans by 100% or more, e.g., at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to a control or reference antibody. In exemplary embodiments, the method includes reducing glycans by at least about 1.5-fold compared to a control or reference antibody. In exemplary embodiments, the method includes reducing glycans by at least about 2-fold compared to a control or reference antibody. In exemplary embodiments, the method includes reducing glycans by at least about 3-fold compared to a control or reference antibody.In exemplary embodiments, the method includes reducing the glycan by at least about 4-fold or about 5-fold compared to a control or reference antibody. In exemplary embodiments, the method includes reducing the glycan by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the method includes reducing the glycan by an amount in the range of at least about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0060] In exemplary aspects, the methods of the disclosure provide for reducing the amount of glycans (e.g., galactosylated glycans, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) of an antibody by at least or about 0.5%, at least or about 1%, at least or about 2%, at least or about 3%, at least or about 5%, at least or about 7%, at least or about 10%, at least or about 15%, at least or about 20%, at least or about 25%, at least or about 30%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 60%, at least or about 70%, at least or about 80%, at least or about 90%, at least or about 100%, at least or about 150%, at least or about 200%, at least or about 250%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, at least or about 1000%, at least or about 1500%, at least or about 2000%, at least or about 30 ... This includes modulating (increasing or decreasing) by at least about 35%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 55%, at least or about 60%, at least or about 65%, at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 96%, at least or about 97%, or at least or about 98%, or by increasing or decreasing by at least or about 0.5% to 98% of the total amount.

[0061] In an exemplary embodiment of the disclosed method, the method includes modulating the amount of galactosylated glycans, e.g., terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species, of the antibody to modulate the ADCP activity of the antibody. In an exemplary aspect, the method includes increasing the amount of galactosylated glycans, e.g., terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species, of the antibody to increase the ADCP activity of the antibody. In an exemplary example, the method includes increasing the amount of galactosylated glycans, e.g., terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species, of trastuzumab by about 1 percent to increase the ADCP activity of the trastuzumab antibody by about 2.5, about 2.8, about 2.88, or about 3 percent. In some examples, the methods include increasing the amount of galactosylated glycans, including, for example, the amount of terminal β-galactose, or the amount of G1, G1a, G1b and / or G2 galactosylated species, of trastuzumab by about 1 percent to increase the ADCP activity of the trastuzumab antibody by about 2.88 percent.

[0062] In an exemplary embodiment, the method includes decreasing the amount of galactosylated glycans of the antibody, e.g., terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species, to decrease the ADCP activity of the antibody. In an exemplary example, the method includes decreasing the amount of galactosylated glycans of the trastuzumab, e.g., terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species, by about 1 percent to decrease the ADCP activity of the trastuzumab antibody by about 2.5, about 2.8, about 2.88, or about 3 percent. In some examples, the method includes decreasing the amount of galactosylated glycans of the trastuzumab, e.g., terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species, by about 1 percent to decrease the ADCP activity of the trastuzumab antibody by about 2.88 percent.

[0063] In an exemplary embodiment of the disclosed method, the method comprises modulating the amount of nonfucosylated glycans of the antibody or the amount of core fucose of the antibody to modulate the ADCP activity of the antibody. In an exemplary aspect, the method comprises increasing the ADCP activity of the antibody by decreasing the amount of nonfucosylated glycans of the antibody or increasing the amount of core fucose of the antibody. In an exemplary aspect, the method comprises decreasing the amount of nonfucosylated glycans of the rituximab antibody by about 1 percent or increasing the amount of core fucose of the rituximab antibody by about 1 percent to increase the ADCP activity of the rituximab antibody by about 0.5, about 0.7, about 0.75, about 0.8, or about 1 percent. In some aspects, the method comprises decreasing the amount of nonfucosylated glycans of the rituximab antibody by about 1 percent or increasing the amount of core fucose of the rituximab antibody by about 1 percent to increase the ADCP activity of the rituximab antibody by about 0.75 percent.

[0064] In other embodiments of the disclosed methods, the method comprises increasing the amount of non-fucosylated glycans or decreasing the amount of core fucose of the antibody, thereby increasing the ADCP activity of the antibody. In exemplary aspects, the method comprises increasing the amount of non-fucosylated glycans of the trastuzumab antibody by about 1 percent, or decreasing the amount of core fucose of the trastuzumab antibody by about 1 percent, thereby increasing the ADCP activity of the trastuzumab antibody by about 0.5, about 0.56, about 0.6, or about 1 percent. In some aspects, the method comprises increasing the amount of non-fucosylated glycans of the trastuzumab antibody by about 1 percent, or decreasing the amount of core fucose of the trastuzumab antibody by about 1 percent, thereby increasing the ADCP activity of the trastuzumab antibody by about 0.56 percent.

[0065] In other exemplary embodiments, the method comprises decreasing the amount of nonfucosylated glycans of the antibody or increasing the amount of core fucose of the antibody to decrease the ADCP activity of the antibody. In exemplary embodiments, the method comprises decreasing the amount of nonfucosylated glycans of the trastuzumab antibody by about 1 percent or increasing the amount of core fucose of the trastuzumab antibody by about 1 percent to decrease the ADCP activity of the trastuzumab antibody by about 0.5, about 0.56, about 0.6, or about 1 percent. In some embodiments, the method comprises decreasing the amount of nonfucosylated glycans of the trastuzumab antibody by about 1 percent or increasing the amount of core fucose of the trastuzumab antibody by about 1 percent to decrease the ADCP activity of the trastuzumab antibody by about 0.56 percent.

[0066] In other embodiments of the disclosed methods, the method comprises increasing the amount of nonfucosylated glycans or decreasing the amount of core fucose of the antibody, thereby decreasing the ADCP activity of the antibody. In exemplary aspects, the method comprises increasing the amount of nonfucosylated glycans of the rituximab antibody by about 1 percent, or decreasing the amount of core fucose of the rituximab antibody by about 1 percent, thereby decreasing the ADCP activity of the rituximab antibody by about 0.5, about 0.7, about 0.75, about 0.8, or about 1 percent. In some aspects, the method comprises increasing the amount of nonfucosylated glycans of the rituximab antibody by about 1 percent, or decreasing the amount of core fucose of the rituximab antibody by about 1 percent, thereby decreasing the ADCP activity of the rituximab antibody by about 0.75 percent.

[0067] In illustrative examples, the non-fucosylated glycans that are modulated (increased or decreased) on a trastuzumab or rituximab antibody include one or more non-fucosylated glycans selected from the group consisting of: A1G0, A1G1, A2G0, A2G1a, A2G1b, A2G2, and A1G1M5.

[0068] In an exemplary embodiment of the disclosed method, the method comprises adjusting the amount of high mannose glycans, including, for example, M5 high mannose species, of the antibody to adjust the ADCP activity of the antibody, for example, an IgG1 antibody. In some examples, the IgG1 antibody is an anti-HER2 antibody or an anti-CD20 antibody. In an exemplary embodiment, the method comprises increasing the amount of high mannose glycans of the anti-HER2 antibody to decrease the ADCP activity of the antibody composition, or decreasing the amount of high mannose glycans of the anti-HER2 antibody to increase the ADCP activity of the antibody composition. In an exemplary example, the method comprises increasing the amount of high mannose glycans of the anti-CD20 antibody to decrease the ADCP activity of the antibody composition, or decreasing the amount of high mannose glycans of the anti-CD20 antibody to increase the ADCP activity of the antibody composition. In an exemplary embodiment, the high mannose glycans that are increased or decreased to modulate ADCP activity in an IgG1 antibody (such as trastuzumab or rituximab) include one or more high mannose species selected from the group consisting of: HM5, HM6, HM7, HM8 and HM9.

[0069] In an exemplary embodiment, the method includes increasing the amount of high mannose glycans, e.g., including M5 high mannose species, of an antibody to decrease ADCP activity of the antibody. In an exemplary example, the method includes increasing the amount of high mannose glycans (e.g., including M5 high mannose species) of an IgG1 antibody (e.g., including trastuzumab or rituximab) by about one percent to decrease ADCP activity of the IgG1 antibody (e.g., including trastuzumab or rituximab) by about 1%, about 1.2%, about 1.31%, about 1.5%, about 1.7%, about 2%, about 2.11%, about 2.5%, or in the range of about 1% to about 2.5%. In some examples, the method includes increasing the amount of high mannose glycans (e.g., including M5 high mannose species) of an IgG1 antibody (e.g., including trastuzumab or rituximab) by about 1 percent to reduce the ADCP activity of the IgG1 antibody (e.g., including trastuzumab or rituximab) by about 1.31% or about 2.11%.

[0070] In an exemplary embodiment, the method includes decreasing the amount of high mannose glycans, e.g., including M5 high mannose species, of an antibody to increase ADCP activity of the antibody. In an exemplary example, the method includes decreasing the amount of high mannose glycans (e.g., including M5 high mannose species) of an IgG1 antibody (e.g., including trastuzumab or rituximab) by about one percent to increase ADCP activity of the IgG1 antibody (e.g., including trastuzumab or rituximab) by about 1%, about 1.2%, about 1.31%, about 1.5%, about 1.7%, about 2%, about 2.11%, about 2.5%, or in the range of about 1% to about 2.5%. In some examples, the method includes reducing the amount of high mannose glycans (e.g., including M5 high mannose species) of an IgG1 antibody (e.g., including trastuzumab or rituximab) by about 1 percent, and increasing the ADCP activity of the IgG1 antibody (e.g., including trastuzumab or rituximab) by about 1.31% or about 2.11%.

[0071] In an exemplary embodiment of the disclosed method, the method comprises modulating the amount of a combination of galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species), non-fucosylated glycans or core fucose, and / or high mannose glycans (e.g., including M5 high mannose species) to modulate ADCP activity of an IgG1 antibody (e.g., including trastuzumab or rituximab). In an exemplary embodiment of the disclosed method, the method comprises modulating ADCP activity of an IgG1 antibody (e.g., including trastuzumab or rituximab) by increasing or decreasing (1) the amount of terminal β-galactose in the antibody and / or the amount of G1, G1a, G1b, and / or G2 galactosylated species of the antibody, (2) the amount of core fucose in the antibody and / or the amount of non-fucosylated species of the antibody, and / or (3) the amount of high mannose in the antibody or the amount of M5 high mannose species of the antibody.

[0072] In some embodiments of the methods of the disclosure, the methods include increasing ADCP activity of an IgG1 antibody (including, for example, trastuzumab or rituximab) by (1) increasing the amount of terminal β-galactose in the antibody or increasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody, (2) decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species of the antibody, and / or (3) decreasing the amount of high mannose in the antibody or decreasing the amount of M5 high mannose species of the antibody.

[0073] In some other embodiments of the methods of the disclosure, the methods include decreasing ADCP activity of an IgG1 antibody (including, for example, trastuzumab or rituximab) by (1) decreasing the amount of terminal β-galactose in the antibody or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody, (2) increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody, and / or (3) increasing the amount of high mannose in the antibody or increasing the amount of M5 high mannose species of the antibody.

[0074] Methods for manipulating the ADCP activity of antibodies The methods provided herein also include methods of matching the ADCP activity of a first reference antibody with the ADCP activity of a second antibody by adjusting the amount of glycans (e.g., galactosylated glycans, terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) in the second antibody to match the ADCP activity of the first reference antibody. In an exemplary example, the method includes altering the ADCP activity of the second antibody to match the ADCP activity of the first reference antibody by adjusting the amount of glycans (e.g., galactosylated glycans, terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or a combination thereof) in the second antibody to match the ADCP activity of the first reference antibody. In an exemplary embodiment, the method includes determining or measuring the ADCP activity of the second antibody and / or the reference antibody using a method described herein. In an exemplary embodiment, the determination or measurement of the ADCP activity of the reference antibody or the second antibody is performed (i) before adjusting the amount of glycans in the antibody, (ii) after adjusting the amount of glycans in the antibody, or (iii) before and after adjusting the amount of glycans in the antibody.

[0075] For example, in some exemplary embodiments of the methods of the present disclosure, the method includes matching the ADCP activity of the reference antibody by (1) determining the ADCP activity of a reference antibody or a reference IgG1 antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference antibody; and (3) altering the ADCP activity of the second antibody by increasing or decreasing the amount of glycan (e.g., galactosylated glycans, terminal β-galactose, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or a combination thereof) of the second antibody such that the ADCP activity of the second antibody after increasing or decreasing the amount of glycan is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference antibody or a reference IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("altering the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0076] In some embodiments, the method comprises matching the ADCP activity of the reference trastuzumab antibody by: (1) determining the ADCP activity of a reference trastuzumab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody; and (3) increasing the ADCP activity of the second antibody by increasing the amount of terminal β-galactose in the second antibody or increasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the second antibody, wherein the ADCP activity of the second antibody after increasing the terminal β-galactose in the second antibody, or the G1, G1a, G1b and / or G2 galactosylated species of the second antibody, is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference trastuzumab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("increasing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0077] In some other embodiments, the method comprises matching the ADCP activity of the reference trastuzumab antibody by: (1) determining the ADCP activity of a reference trastuzumab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody; and (3) reducing the ADCP activity of the second antibody by reducing the amount of terminal β-galactose in the second antibody or reducing the amount of G1, G1a, G1b and / or G2 galactosylated species in the second antibody, wherein the ADCP activity of the second antibody after reducing the terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species in the second antibody is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference trastuzumab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("reducing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0078] In some embodiments, the method comprises matching the ADCP activity of the reference trastuzumab antibody by: (1) determining the ADCP activity of a reference trastuzumab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody; and (3) increasing the ADCP activity of the second antibody by decreasing the amount of core fucose in the second antibody or increasing the amount of non-fucosylated species of the second antibody, wherein the ADCP activity of the second antibody after decreasing the core fucose or increasing the amount of non-fucosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference trastuzumab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("increasing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0079] In some embodiments, the method comprises matching the ADCP activity of the reference trastuzumab antibody by: (1) determining the ADCP activity of a reference trastuzumab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody; and (3) decreasing the ADCP activity of the second antibody by increasing the amount of core fucose in the second antibody or decreasing the amount of non-fucosylated species of the second antibody, wherein the ADCP activity of the second antibody after increasing the core fucose or decreasing the amount of non-fucosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference trastuzumab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("reducing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0080] In some embodiments, the method comprises matching the ADCP activity of the reference rituximab antibody by: (1) determining the ADCP activity of a reference rituximab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference rituximab antibody; and (3) increasing the ADCP activity of the second antibody by increasing the amount of core fucose in the second antibody or decreasing the amount of non-fucosylated species of the second antibody, wherein the ADCP activity of the second antibody after increasing the core fucose or decreasing the non-fucosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference rituximab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("increasing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0081] In some embodiments, the method comprises matching the ADCP activity of the reference rituximab antibody by: (1) determining the ADCP activity of a reference rituximab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference rituximab antibody; and (3) decreasing the ADCP activity of the second antibody by decreasing the amount of core fucose in the second antibody or increasing the amount of non-fucosylated species of the second antibody, wherein the ADCP activity of the second antibody after decreasing the core fucose or increasing the non-fucosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference rituximab antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("reducing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0082] In some embodiments, the method comprises matching the ADCP activity of a reference IgG1 antibody (e.g., comprising trastuzumab or rituximab) by: (1) determining the ADCP activity of a reference IgG1 antibody (e.g., comprising trastuzumab or rituximab); (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference antibody; and (3) increasing the ADCP activity of the second antibody by reducing the amount of high mannose in the second antibody or reducing the amount of M5 high mannose species of the second antibody, wherein the ADCP activity of the second antibody after reducing the high mannose or M5 high mannose species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("increasing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0083] In some embodiments, the method comprises matching the ADCP activity of a reference IgG1 antibody (e.g., comprising trastuzumab or rituximab) by: (1) determining the ADCP activity of a reference IgG1 antibody (e.g., comprising trastuzumab or rituximab); (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference antibody; and (3) decreasing the ADCP activity of the second antibody by increasing the amount of high mannose in the second antibody or by increasing the amount of M5 high mannose species of the second antibody, wherein the ADCP activity of the second antibody after increasing the high mannose or M5 high mannose species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within about 1% to about 35% of the reference antibody. In some examples, step 1 ("determining the ADCP activity of a reference IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining the ADCP activity of a ... second antibody") and / or step 3 ("reducing the ADCP activity of a ... second antibody"), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0084] In addition to methods for matching the ADCP of a reference antibody, the methods provided herein also include methods for engineering an antibody with a specific ADCP activity by adjusting the amount of glycans (e.g., galactosylated glycans, terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) of the antibody to achieve a desired ADCP activity.

[0085] For example, in some exemplary embodiments of the methods of the present disclosure, the methods include (1) determining the ADCP activity of the antibody or IgG1 antibody; (2) determining or identifying a target ADCP activity; and (3) altering the ADCP activity of the antibody by increasing or decreasing the amount of glycan (e.g., galactosylated glycan, terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycan, core fucose, high mannose glycan, M5 high mannose species, or a combination thereof) of the antibody such that the ADCP activity of the antibody after increasing or decreasing the amount of glycan is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of an antibody or IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("altering the ADCP activity of the antibody..."), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0086] In some embodiments, the method comprises engineering a specific target ADCP activity of a trastuzumab antibody by the steps of: (1) determining an ADCP activity of the trastuzumab antibody; (2) determining or identifying a target ADCP activity; and (3) increasing the amount of terminal β-galactose in the antibody, or increasing the amount of G1, G1a, G1b and / or G2 galactosylated species in the antibody, wherein the ADCP activity of the trastuzumab antibody after increasing the terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species in the antibody, is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of a trastuzumab antibody") occurs before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("increasing the ADCP activity of a trastuzumab antibody..."), while in other examples, step 2 occurs before, after, or simultaneously with step 1 and / or step 3.

[0087] In some other embodiments, the method comprises manipulating a specific target ADCP activity of a trastuzumab antibody by the steps of: (1) determining an ADCP activity of the trastuzumab antibody; (2) determining or identifying a target ADCP activity; and (3) reducing the amount of terminal β-galactose in the antibody, or reducing the amount of G1, G1a, G1b and / or G2 galactosylated species in the antibody, wherein the ADCP activity of the trastuzumab antibody after reducing terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species in the antibody, is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of a trastuzumab antibody") occurs before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("reducing the ADCP activity of a trastuzumab antibody..."), while in other examples, step 2 occurs before, after, or simultaneously with step 1 and / or step 3.

[0088] In some embodiments, the method comprises manipulating a specific target ADCP activity of a trastuzumab antibody by the steps of: (1) determining an ADCP activity of the trastuzumab antibody; (2) determining or identifying a target ADCP activity; and (3) increasing the ADCP activity of the trastuzumab antibody by decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species of the antibody, wherein the ADCP activity of the trastuzumab antibody after decreasing core fucose or increasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of a trastuzumab antibody") occurs before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("increasing the ADCP activity of a trastuzumab antibody..."), while in other examples, step 2 occurs before, after, or simultaneously with step 1 and / or step 3.

[0089] In some embodiments, the method comprises manipulating a specific target ADCP activity of a trastuzumab antibody by the steps of: (1) determining an ADCP activity of the trastuzumab antibody; (2) determining or identifying a target ADCP activity; and (3) decreasing the ADCP activity of the trastuzumab antibody by increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody, wherein the ADCP activity of the trastuzumab antibody after increasing core fucose or decreasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of a trastuzumab antibody") occurs before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("reducing the ADCP activity of a trastuzumab antibody..."), while in other examples, step 2 occurs before, after, or simultaneously with step 1 and / or step 3.

[0090] In some embodiments, the method comprises manipulating a specific target ADCP activity of a rituximab antibody by the steps of: (1) determining an ADCP activity of the rituximab antibody; (2) determining or identifying a target ADCP activity; and (3) increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody, wherein the ADCP activity of the rituximab antibody after increasing core fucose or decreasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of a rituximab antibody") is performed before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("increasing the ADCP activity of a rituximab antibody..."), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0091] In some embodiments, the method comprises manipulating a specific target ADCP activity of a rituximab antibody by: (1) determining an ADCP activity of the rituximab antibody; (2) determining or identifying a target ADCP activity; and (3) decreasing the ADCP activity of the rituximab antibody by decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species of the antibody, wherein the ADCP activity of the rituximab antibody after decreasing core fucose or increasing non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of a rituximab antibody") occurs before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("reducing the ADCP activity of a rituximab antibody..."), while in other examples, step 2 occurs before, after, or simultaneously with step 1 and / or step 3.

[0092] In some embodiments, the method comprises engineering a particular target ADCP activity of an IgG1 antibody (e.g., comprising trastuzumab or rituximab) by the steps of: (1) determining the ADCP activity of an IgG1 antibody (e.g., comprising trastuzumab or rituximab); (2) determining or identifying a target ADCP activity; and (3) increasing the ADCP activity of the IgG1 antibody (e.g., comprising trastuzumab or rituximab) by reducing the amount of high mannose in the antibody or reducing the amount of M5 high mannose species of the antibody, wherein the ADCP activity of the IgG1 antibody (e.g., comprising trastuzumab or rituximab) after reducing the high mannose or M5 high mannose species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of an IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("increasing the ADCP activity of an IgG1 antibody..."), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0093] In some embodiments, the method comprises manipulating a particular target ADCP activity of an IgG1 antibody (e.g., comprising trastuzumab or rituximab) by: (1) determining the ADCP activity of a reference IgG1 antibody (e.g., comprising trastuzumab or rituximab); (2) determining or identifying a target ADCP activity; and (3) decreasing the ADCP activity of the IgG1 antibody (e.g., comprising trastuzumab or rituximab) by increasing the amount of high mannose in the antibody or increasing the amount of M5 high mannose species of the antibody, wherein the ADCP activity of the IgG1 antibody (e.g., comprising trastuzumab or rituximab) after increasing the high mannose or M5 high mannose species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within about 1% to about 35% of the target ADCP activity. In some examples, step 1 ("determining the ADCP activity of an IgG1 antibody") is performed before, after, or simultaneously with step 2 ("determining or identifying a target ADCP activity") and / or step 3 ("reducing the ADCP activity of an IgG1 antibody..."), while in other examples, step 2 is performed before, after, or simultaneously with step 1 and / or step 3.

[0094] Methods for Modulating Glycans Suitable methods for modulating the amount of glycans (such as galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species), non-fucosylated glycans or glycans containing core fucose, and / or high mannose glycans (e.g., including M5 high mannose species) on glycoproteins, including antibodies, are known in the art. See, e.g., Zhang et al., Drug Discovery Today 21(5):2016. Thus, in some embodiments, glycosylation-competent cells (which can be used to recombinantly produce glycoproteins, e.g., antibodies) are cultured under specific conditions to achieve a desired level of glycans.

[0095] For example, WO 2013 / 114164, WO 2013 / 114245, WO 2013 / 114167, WO 2015128793, and WO 2016 / 089919 each describe recombinant cell culture techniques useful for modulating glycans, e.g., galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species), non-fucosylated glycans, or glycans containing core fucose, and / or high mannose glycans (e.g., including M5 high mannose species), e.g., to obtain glycoproteins with an increased proportion of total non-fucosylated glycans. (WO 2013 / 114164), obtaining glycoproteins with an increased proportion of Man5 glycans and / or nonfucosylated glycans (WO 2013 / 114245), obtaining glycoproteins with specific amounts of high mannose glycans, nonfucosylated glycans and G0F glycans (WO 2013 / 114167); obtaining glycoproteins with high mannose glycans and reduced galactosylated and / or highly galactosylated glycans (WO 2015 / 128793); and manipulating the fucosylated glycan content on recombinant proteins (WO 2016 / 089919). Cell culture methods described by WO 2013 / 114164, WO 2013 / 114245, WO 2013 / 114167, WO 2015 / 128793, and WO 2016 / 089919 include modifying one or more cell culture parameters, such as temperature, pH, culturing the cells with manganese ions or a salt thereof (e.g., 0.35 μM to about 20 μM manganese), and / or culturing the cells with copper (e.g., 10-100 ppb) and manganese (e.g., 50-1000 nM) to modulate specific glycans.

[0096] Additionally, WO 2015 / 140700 describes culturing cells in the presence of betaine to increase nonfucosylated glycans, or culturing cells with manganese, galactose, and betaine to obtain target values ​​of mannosylated, galactosylated, and nonfucosylated glycans. US 2014 / 0356910 teaches how to increase high mannose glycoforms by manipulating the mannose to total hexose ratio in cell culture medium formulations. Pacis et al., Biotechnology and Bioengineering 108(10):2348-2358 (2011) teaches obtaining high levels of Man5 glycans by increasing the osmolality level of the cell culture medium and extending the culture period. Similarly, Konno et al., Cytotechnology 64:249-3+6 (2012) describes a method to control antibody fucose content by the osmolality of the culture medium. Wong et al., Biotechnology and Bioengineering 89(2):164-177 (2004) teaches a method to reduce recombinant protein sialylation and increase high mannose glycans by using low glutamine fed-batch culture. WO 2017 / 079165 describes a method to increase or decrease the non-fucosylated or fucosylated forms of recombinant proteins by using host cells genetically engineered to have no GMD or FX and culturing the host cells with fucose. WO 2017 / 134667 describes culturing cells with nicotinamide and fucose to produce antibodies with reduced levels of non-fucosylation. Sha et al., TIBs 34(10):835-846 (2016) also outline several methods for modulating glycans, including increasing the level of galactosylation on antibodies by incubation with uridine, manganese, and galactose, and using mannose as a carbon source to increase high mannose glycoforms.

[0097] Thus, the methods of the disclosure, in exemplary embodiments, include employing one or more of the procedures, cell culture media, and / or cell culture conditions taught in any one or more of the above references or other references described herein to modulate the amount of galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species), non-fucosylated or core fucose-containing glycans, and / or high mannose glycans (e.g., including M5 high mannose species). In exemplary embodiments, the methods include culturing glycosylation-competent cells expressing an antibody in cell culture media under conditions that modulate the levels of galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b, and / or G2 galactosylated species), non-fucosylated or core fucose-containing glycans, and / or high mannose glycans (e.g., including M5 high mannose species). For example, the methods, in some embodiments, include culturing glycosylation-competent cells expressing the antibody in a cell culture medium under conditions that modulate glycan levels, the cell culture medium comprising fucose, or fucose and glucose.

[0098] In the method comprising maintaining or culturing cells in cell culture, the cell culture can be maintained according to any set of conditions suitable for recombinant glycosylated protein or antibody production. For example, in some embodiments, the cell culture is maintained at a specific pH, temperature, cell density, culture volume, dissolved oxygen level, pressure, osmolality, etc. In an exemplary embodiment, the pre-inoculated cell culture is shaken (e.g., at 70 rpm) in a CO2 incubator under standard humidified conditions at 5% CO2. In an exemplary embodiment, the method comprises culturing glycosylation-competent cells expressing an antibody in a cell culture medium under conditions that regulate the level of glycans, e.g., increasing the osmolality of the cell culture medium to reduce the level of non-fucosylated glycans of the antibody, as taught by Konno et al. (supra). In an exemplary embodiment, the method includes culturing glycosylation-competent cells expressing the antibody in a cell culture medium under conditions that modulate the level of glycans, e.g., modulating the pH and temperature of the cell culture, as taught by WO 2013 / 114164, WO 2013 / 114245, WO 2013 / 114167, or WO 2015 / 128793 (each of which is incorporated by reference herein).

[0099] In an exemplary embodiment, the method of the disclosure includes maintaining glycosylation-competent cells in a cell culture medium at a pH, temperature, osmolality, and dissolved oxygen level suitable for the production of a recombinant glycosylated protein or antibody, as is well known in the art. In an exemplary embodiment, the cell culture is maintained in a medium suitable for cell growth and / or is provided with one or more feed media according to any suitable feeding schedule, as is well known in the art.

[0100] In an exemplary embodiment, the glycosylation competent cell is a eukaryotic cell, including but not limited to a yeast cell, a filamentous fungal cell, a protist cell, an algae cell, an insect cell, or a mammalian cell. Such host cells are described in the art. See, for example, Frenzel, et al., Front Immunol 4:217 (2013). In an exemplary embodiment, the eukaryotic cell is a mammalian cell. In an exemplary embodiment, the mammalian cell is a non-human mammalian cell. In some embodiments, the cells are selected from the group consisting of Chinese hamster ovary (CHO) cells and derivatives thereof (e.g., CHO-K1, CHO pro-3), mouse myeloma cells (e.g., NS0, GS-NS0, Sp2 / 0), cells engineered to lack dihydrofolate reductase (DHFR) activity (e.g., DUKX-X11, DG44), human embryonic kidney 293 (HEK293) cells or derivatives thereof (e.g., HEK293T, HEK293-EBNA), African green monkey kidney cells (e.g., COS cells, VERO cells), human cervical cancer cells (e.g., HeLa), human bone osteosarcoma epithelial cells U2-OS, adenocarcinoma human alveolar basal epithelial cells A549, human fibrosarcoma cells HT1080, mouse brain tumor cells CAD, embryonal carcinoma cells P19, mouse embryonic fibroblast cells NIH 3T3, mouse fibroblast L929, mouse neuroblastoma N2a, human breast cancer MCF-7, retinoblastoma Y79, human retinoblastoma SO-Rb50, human hepatocellular carcinoma Hep G2, mouse B myeloma J558L or baby hamster kidney (BHK) cells (Gaillet et al. 2007; Khan, Adv Pharm Bull 3(2):257-263(2013)).

[0101] Cells that are not competent for glycosylation can also be transformed into glycosylation-competent cells, for example, by introducing into them genes encoding the relevant enzymes required for glycosylation. Exemplary enzymes include, but are not limited to, oligosaccharyltransferase, glycosidase, glucosidase I, glucosidase II, calnexin / calreticulin, glycosyltransferase, mannosidase, GlcNAc transferase, galactosyltransferase, and sialyltransferase.

[0102] In further or alternative aspects, glycosylation competent cells recombinantly producing antibodies are engineered to modulate the glycans of the antibodies, such as galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species), non-fucosylated glycans or glycans containing core fucose, and / or high mannose glycans (e.g., including M5 high mannose species). In exemplary aspects, glycosylation competent cells are engineered to alter the activity of an enzyme in the de novo or salvage pathway. Optionally, glycosylation competent cells are engineered to knock out a gene encoding GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductase. In exemplary embodiments, glycosylation competent cells are engineered to alter the activity of an enzyme in the de novo or salvage pathway. These two pathways of fucose metabolism are well known in the art and are depicted in FIG. 1C. In an exemplary embodiment, the glycosylation competent cells are engineered to alter the activity of any one or more of fucosyl-transferases (FUTs, e.g., FUT1, FUT2, FUT3, FUT4, FUT5, FUT6, FUT7, FUT8, FUT9), fucose kinase, GDP-fucose pyrophosphorylase, GDP-D-mannose-4,6-dehydratase (GMD), and GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductase (FX). In an exemplary embodiment, the glycosylation competent cells are engineered to knock out the gene encoding FX. In an exemplary embodiment, the glycosylation competent cells are engineered to alter the activity of β(1,4)-N-acetylglucosaminyltransferase III (GNTIII) and / or GDP-6-deoxy-D-lyxo-4-hexulose reductase (RMD). In an exemplary aspect, the glycosylation competent cells are engineered to overexpress GNTIII and / or RMD. In an exemplary embodiment, the glycosylation competent cells are engineered to have altered beta-galactosyltransferase activity.In some embodiments, glycosylation competent cells are genetically engineered to modulate the expression levels of genes encoding GDP-keto-6-deoxymannose-3,5-epimerase, 4-reductase, β1-4 galactosyltransferase, and / or β1-4 N-acetylgalactosaminyltransferase.

[0103] Several methods are known in the art to reduce or eliminate fucosylation of Fc-containing molecules, such as antibodies. These include recombinant expression in certain mammalian cell lines, including FUT8 knockout cell lines, mutant CHO line Lec13, rat hybridoma cell line YB2 / 0, cell lines containing small interfering RNA specific for the FUT8 gene, and cell lines co-expressing β-1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Alternatively, Fc-containing molecules can be expressed in non-mammalian cells, such as plant cells, yeast, or prokaryotic cells (e.g., E. coli).

[0104] In exemplary embodiments, the target glycan amount is achieved by chemical or enzymatic treatment of the antibody after production. In exemplary embodiments, the methods of the present disclosure include treating the antibody chemically or enzymatically after the antibody is recombinantly produced. In exemplary embodiments, the chemical or enzyme is selected from the group consisting of Endo-S, Endo-S2, Endo-D, Endo-M, Endo-LL, α-fucosidase, β-(1-4)-galactosidase, Endo-H, Endo-F1, Endo-F2, Endo-F3, β-1,4-galactosyltransferase, kifunensine, and PNGase-F. In exemplary embodiments, the chemical or enzyme is incubated with the antibody for various times to generate antibodies with various amounts of glycans. In some embodiments, the antibody is incubated with β-1,4-galactosyltransferase, as described in the Examples. In some further embodiments, antibodies with varying levels of galactose can be generated by incubating the antibodies with β-1,4-galactosyltransferase for a period of time, such as, but not limited to, about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 9 hours, or a period of time ranging from about 10 minutes to about 9 hours.

[0105] How to measure glycans A variety of methods are known in the art for assessing glycoforms present in a glycoprotein-containing composition, e.g., an antibody, or for determining, detecting, or measuring the glycoform profile of a particular sample containing a glycoprotein. Suitable methods include, but are not limited to, hydrophilic interaction liquid chromatography (HILIC), liquid chromatography-tandem mass spectrometry (LC-MS), positive ion MALDI-TOF analysis, negative ion MALDI-TOF analysis, HPLC, weak anion exchange (WAX) chromatography, normal phase chromatography (NP-HPLC), exoglycosidase digestion, Biogel P-4 chromatography, anion exchange chromatography, and one-dimensional NMR spectroscopy, and combinations thereof. For example, Pace et al.,Biotechnol.Prog.,2016,Vol.32,No.5 pages 1181-1192, Shah,B.et al.J.Am.Soc.Mass Spectrom.(2014)25:999, Mattu et al.,JBC 273:2260-2272(1998), Field et al.,Biochem J 299(Pt 1):261-275(1994), Yoo et al.,MAbs 2(3):320-334(2010),Wuhrer M.et al.,Journal of Chromatography B,2005,Vol.825,Issue 2,pages 124-133,Ruhaak LR,Anal Bioanal Chem, 2010, Vol. 397: 3457-3481; Kurogochi et al., PLOS One 10(7): e0132848; doi: 10.1371 / journal.pone.0132848; Thomann et al., PLOS One 10(8): e0134949. doi: 10.1371 / journal.pone.0134949; Pace et al., Biotechnol. Prog. 32(5): 1181-1192 (2016); and Geoffrey, RGet. al. Analytical Biochemistry 1996, Vol. 240, pages 210-226.The examples provided herein also describe methods suitable for assessing the glycoforms present in a glycoprotein-containing composition, such as an antibody.

[0106] Control As described herein, some of the methods of the present disclosure include modulation (e.g., increase or decrease) provided by such methods compared to a "control" or "reference antibody." In exemplary embodiments, with respect to ADCP activity or glycan amount, the "control" is the ADCP activity level and / or glycan amount of an antibody or composition (e.g., a reference antibody) prior to experimental intervention directed toward modulation of ADCP activity and / or modulation of glycan profile, such as the ADCP activity level and / or glycan amount of the antibody or composition (e.g., a reference antibody) when first measured or determined. In certain embodiments, the "control" or "reference antibody" may be an antibody that has undergone significant experimental intervention directed toward modulation of ADCP activity and / or modulation of glycan profile, but where further modulation of ADCP activity and / or glycan profile is desired. In these examples, the "control" is the ADCP activity level and / or glycan amount of an antibody or composition (e.g., a reference antibody) prior to further experimental intervention directed toward further modulation of ADCP activity and / or further modulation of glycan profile.

[0107] Antibodies, fragments and protein products As used herein, the term "antibody" refers to a protein having a conventional immunoglobulin configuration, including heavy and light chains, and including variable and constant regions. For example, an antibody may be an IgG, which is a "Y-shaped" structure consisting of two identical pairs of polypeptide chains, each pair having one "light" chain (usually having a molecular weight of about 25 kDa) and one "heavy" chain (usually having a molecular weight of about 50-70 kDa). An antibody has a variable region and a constant region. In the IgG type, the variable region is generally about 100-110 or more amino acids, contains three complementarity determining regions (CDRs), and is primarily responsible for antigen recognition and is substantially different from other antibodies that bind to different antigens. See, for example, Janeway et al., "Structure of the Antibody Molecule and the Immunoglobulin Genes", Immunobiology: The Immune System in Health and Disease, 4 th See ed. Elsevier Science Ltd. / Garland Publishing, (1999).

[0108] The term "antibody fragment" or "antibody fragment thereof" refers to a portion of an intact antibody. An "antigen-binding fragment" or "antigen-binding fragment thereof" refers to a portion of an intact antibody that binds to an antigen. An antigen-binding fragment may include the antigen-determining variable region of an intact antibody. Examples of antigen-binding fragments of an antibody fragment include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, scFv, and single chain antibodies.

[0109] The term "IgG" as used herein refers to a polypeptide belonging to the class of antibodies substantially encoded by recognized immunoglobulin gamma genes. In humans, this class includes IgG1, IgG2, IgG3, and IgG4. In mice, this class includes IgG1, IgG2a, IgG2b, and IgG3. The sequences of the heavy chains of human IgG1, IgG2, IgG3, and IgG4 can be found in many sequence databases, for example in the Uniprot database (www.uniprot.org) under accession numbers P01857 (IGHG1_HUMAN), P01859 (IGHG2_HUMAN), P01860 (IGHG3_HUMAN), and P01861 (IGHG1_HUMAN), respectively. In preferred embodiments, the methods and antibodies disclosed herein relate to IgG1 antibodies. In some other preferred embodiments, the methods and antibodies disclosed herein relate to human IgG1 antibodies.

[0110] The term "CDR" and its plural "CDRs" refer to the complementarity determining regions, three of which constitute the binding properties of the light chain variable region (CDR-L1, CDR-L2 and CDR-L3) and three of which constitute the binding properties of the heavy chain variable region (CDR-H1, CDR-H2 and CDR-H3). The CDRs contain most of the residues responsible for the specific interaction of the antibody with the antigen and thus contribute to the functional activity of the antibody molecule. The CDRs are the primary determinants of antigen specificity.

[0111] The exact definition of the boundaries and lengths of CDRs are subject to various classification and numbering systems. Thus, CDRs may be represented by Kabat, Chothia, contact, or any other boundary definition, including the numbering systems described herein. Although the boundaries are different, each of these systems has some overlap in the parts that constitute the so-called "hypervariable regions" in the variable sequences. Thus, the definitions of CDRs according to these systems may differ in length and in the boundary regions with respect to the adjacent framework regions. See, for example, Kabat (an approach based on interspecies sequence variability), Chothia (an approach based on crystallographic studies of antigen-antibody complexes), and / or MacCallum (Kabat et al., supra; Chothia et al., J.MoI.Biol, 1987, 196:901-917; and MacCallum et al., J.MoI.Biol, 1996, 262:732). Yet another standard for the characterization of antigen-binding sites is the AbM definition used by Oxford Molecular's AbM antibody modeling software.See, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains.In:Antibody Engineering Lab Manual (Ed.:Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg).As long as two residue identification techniques define overlapping but non-identical regions, they can be combined to define hybrid CDRs.However, the so-called Kabat numbering system is preferred.See, for example, Chothia and Lesk, J.MoI.Biol., 1987,196:901; Chothia et al., Nature, 1989,342:877; Martin and Thornton, J.MoI.Biol, 1996,263:800; Antibodies:A Laboratory Manual, Cold Spring Harbor Laboratory, eds.Harlow et al., 1988. Each of the documents is incorporated herein by reference.

[0112] The term "variable" refers to that portion of an antibody or immunoglobulin domain (i.e., the "variable domain") that exhibits variability in sequence and is responsible for determining the specificity and binding affinity of a particular antibody. The variable heavy chain (VH) and variable light chain (VL) pair together to form a single antigen-binding site.

[0113] The variability is not uniformly distributed throughout the variable domain of an antibody, but is concentrated in subdomains of each of the heavy and light chain variable regions. These subdomains are called "hypervariable regions" or "complementarity determining regions" (CDRs). The more conserved (i.e. non-hypervariable) parts of the variable domains are called "framework" regions (FRMs or FRs) and provide a scaffold for the six CDRs in the three-dimensional space that form the antigen-binding surface. Naturally occurring heavy and light chain variable domains each contain four FRM regions (FR1, FR2, FR3 and FR4) that largely adopt a β-sheet configuration, which are connected by three hypervariable regions that form loop connections and sometimes form part of the β-sheet structure. The hypervariable regions of each chain are held together in close proximity by the FRMs and contribute to the formation of the antigen-binding site with the hypervariable regions of the other chain (see Kabat et al., supra).

[0114] The terms "Fc domain", "Fc region" and "IgG Fc domain" as used herein refer to a portion of an immunoglobulin, e.g., an IgG molecule, that correlates with the crystallizable fragment obtained by papain digestion of the IgG molecule. The Fc region comprises the C-terminal halves of the two heavy chains of an IgG molecule linked by disulfide bonds. It does not have antigen-binding activity, but contains carbohydrate moieties and sites that bind to complement receptors and Fc receptors, e.g., the FcRn receptor. For example, the Fc domain comprises the entire second constant domain CH2 (residues at EU positions 231-340 of human IgG1) and the third constant domain CH3 (residues at EU positions 341-447 of human IgG1).

[0115] Fc may refer to this region in isolation or in the context of an antibody or antibody fragment. Polymorphisms have been observed at many positions in the Fc domain, including but not limited to EU positions 270, 272, 312, 315, 356, and 358. Thus, "wild type IgG Fc domain" or "WT IgG Fc domain" refers to a naturally occurring IgG Fc region (i.e., any allele). Fc mutants, Fc fragments, Fc variants, and Fc derivatives are described, for example, in U.S. Pat. Nos. 5,624,821, 5,885,573, 5,677,425, 6,165,745, 6,277,375, 5,869,046, 6,121,022, 5,624,821, 5,648,260, 6,528,624, 6,194,551, 6,737,056, and 7,122,637. The details are described in U.S. Patent Application Publication Nos. 7,183,387, 7,332,581, 7,335,742, 7,371,826, 6,821,505, 6,180,377, 7,317,091, 7,355,008, U.S. Patent Application Publication No. 2004 / 0002587, and WO 99 / 058572, WO 2011 / 069164, and WO 2012 / 006635.

[0116] The Fc region generally determines the antibody effector functions that occur after antigen binding. It can recruit molecules of the innate immune system such as C1q, as well as cytotoxic and antigen-presenting cells through binding interactions with Fcγ receptors. The IgG Fc region contains two conserved N-glycosylation sites (one on each heavy chain) at Asn297 (see PM Rudd. Glycosylation and the immune system. Science, 291 (2001), pp. 2370-2376). Variation of the structural glycans at ASN297 results in subtle changes in structure that affect the interaction of IgG with the immune system. For example, Fc region glycans can be modified by altering the structure of the Fc region (see S. Krapp, et al. Structural analysis of human IgG-Fc glycoforms reveals correlation between glycosylation and structural integrity J. Mol. Biol., 325 (2003); 979-98931; Y. Mimura, et al. Role of oligosaccharide residues of IgG1-Fc in Fc RIIb binding J. Biol. Chem., 276 (2001), 45539-45547) or by glycan-glycan interactions (C. Ferrara, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc(RIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA, 108 (2011), 12669-12674), which can directly affect the affinity of IgG for Fcγ receptors and, as a consequence, strongly influence their ability to recruit immune effector cells.See also Zhang et al. Challenges of glycosylation analysis and control: an integrated approach to producing optimal and consistent therapeutic drugs. Drug Discovery Today, (21) 5 (2016) 740-765.

[0117] The term "monoclonal antibody" (mAb) as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., an individual antibody comprising the population that is identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site or determinant on the antigen, in contrast to conventional (polyclonal) antibody preparations that typically contain different antibodies directed against different determinants (or epitopes). In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture and are therefore uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method.

[0118] For the preparation of monoclonal antibodies, any technique that provides antibodies produced by continuous cell line cultures can be used. For example, the monoclonal antibodies used can be made by the hybridoma method first described by Koehler et al., Nature, 256:495 (1975), or by recombinant DNA methods (see, for example, U.S. Patent No. 4,816,567). Additional examples of techniques for producing human monoclonal antibodies include the trioma technique, the human B-cell hybridoma technique (Kozbor, Immunology Today 4 (1983), 72), and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96).

[0119] The hybridomas can then be screened using standard methods, such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (BIACORE™) analysis, to identify one or more hybridomas that produce antibodies that specifically bind to the designated antigen. Any form of the relevant antigen can be used as the immunogen, for example, recombinant antigen, naturally occurring form, any variant or fragment thereof, as well as antigenic peptides thereof. Surface plasmon resonance, as employed in the BIAcore system, can be used to increase the efficiency of binding of phage antibodies to epitopes of target antigens (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).

[0120] Another exemplary method for generating monoclonal antibodies includes screening protein expression libraries, such as phage display or ribosome display libraries, as described, for example, in Ladner et al., U.S. Pat. No. 5,223,409, Smith (1985) Science 228:1315-1317, Clackson et al., Nature, 352:624-628 (1991), and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0121] In addition to using display libraries, the relevant antigens can be used to immunize non-human animals, such as rodents (such as mice, hamsters, rabbits, or rats). In one embodiment, the non-human animals contain at least a portion of a human immunoglobulin gene. For example, mouse strains deficient in mouse antibody production can be engineered with large fragments of the human Ig (immunoglobulin) locus. Hybridoma technology can be used to generate and select antigen-specific monoclonal antibodies derived from genes with the desired specificity. See, for example, XENOMOUSE™, Green et al. (1994) Nature Genetics 7:13-21, US Patent Publication No. 2003-0070185, WO 96 / 34096, and WO 96 / 33735.

[0122] Monoclonal antibodies can also be obtained from non-human animals and then modified, e.g., humanized, deimmunized, chimerized, etc., using recombinant DNA techniques known in the art. Examples of modified antibody constructs include humanized variants of non-human antibodies, "affinity matured" antibodies (see, e.g., Hawkins et al. J. Mol. Biol. 254, 889-896 (1992) and Lowman et al., Biochemistry 30, 10832-10837 (1991)), and antibody variants with altered effector functions (see, e.g., U.S. Pat. No. 5,648,260; Kontermann and Duebel (2010), supra; and Little (2009), supra).

[0123] Monoclonal antibodies according to the invention include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical or homologous to corresponding sequences in antibodies from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of interest herein include "primatized" antibodies that contain variable domain antigen-binding sequences derived from a non-human primate (e.g., Old World monkeys, apes, etc.) and human constant region sequences. Various techniques for producing chimeric antibodies have been described. See, e.g., Morrison et al., Proc. Natl. Acad. ScL USA 81:6851, 1985; Takeda et al., Nature 314:452, 1985; Cabilly et al., U.S. Pat. No. 4,816,567; Boss et al., U.S. Pat. No. 4,816,397; Tanaguchi et al., EP 0171496; EP 0173494; and GB 2177096.

[0124] Humanized antibodies can also be produced using transgenic animals such as mice that express human heavy and light chain genes but cannot express endogenous mouse immunoglobulin heavy and light chain genes. Winter describes an exemplary CDR grafting method that can be used to prepare the humanized antibodies described herein (U.S. Pat. No. 5,225,539). All of the CDRs of a particular human antibody can be replaced with at least a portion of a non-human CDR, or only a portion of the CDRs can be replaced with a non-human CDR. It is only necessary to replace as many CDRs as are required for the binding of the humanized antibody to a given antigen.

[0125] Humanized antibodies can be optimized by introducing conservative substitutions, consensus sequence substitutions, germline substitutions and / or back mutations. Such modified immunoglobulin molecules can be generated by any of several techniques known in the art (e.g., Teng et al., Proc. Natl. Acad. Sci. USA, 80:7308-7312, 1983; Kozbor et al., Immunology Today, 4:7279, 1983; Olsson et al., Meth. Enzymol., 92:3-16, 1982, and EP 0239400).

[0126] The term "human antibody" includes antibodies having antibody regions, such as variable and constant regions or domains, that substantially correspond to human germline immunoglobulin sequences known in the art, including, for example, those described by Kabat et al. (1991) supra. The human antibodies, antibody constructs or binding domains of the invention may contain amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs, particularly CDR3. The human antibodies, antibody constructs or binding domains may have at least one, two, three, four, five or more positions substituted with amino acid residues not encoded by human germline immunoglobulin sequences. The definition of human antibodies, antibody constructs and binding domains as used herein also contemplates fully human antibodies, which contain only human sequences of non-artificially and / or genetically modified antibodies, which may be obtained by using techniques or systems such as Xenomouse.

[0127] Advantageously, the method described herein relates to an antibody comprising an Fc domain, and in an exemplary embodiment, an IgG1 antibody. In an exemplary embodiment, the antibody is an IgG1 antibody having a specific antibody sequence. The term "antibody sequence" refers to the amino acid sequence of an antibody. As used herein, the phrase "having the same sequence as a reference antibody" refers to an antibody having an amino acid sequence identical to the amino acid sequence of the complementarity determining region (CDR), variable heavy chain (VH) and / or variable light chain (VL) of the reference antibody. In a preferred embodiment, an antibody "having the same sequence as a reference antibody" as used herein refers to an antibody having the same CDR, VH and VL amino acid sequences as the CDR, VH and VL sequences of the reference antibody.

[0128] In an exemplary embodiment, the IgG1 antibody is an anti-EGFR antibody, e.g., an anti-HER2 monoclonal antibody. In an exemplary embodiment, the IgG1 antibody is trastuzumab, or a biosimilar thereof. The term trastuzumab refers to an IgG1 kappa humanized monoclonal antibody that binds to the HER2 / neu antigen, comprising the VH and VL, or VH-IgG1 and VL-IgGkappa sequences, as listed in Table 1, i.e., as set forth in SEQ ID NOs: 1-8, 21 or 22 (see CAS No.: 180288-69-1; DrugBank-DB00072; Kyoto Encyclopedia of Genes and Genomes (KEGG) entry D03257).

[0129] [Table 1]

[0130] In some examples, the trastuzumab antibody comprises: (a) a light chain variable domain comprising (i) a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:1, (ii) a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:2, and (iii) a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; and (b) a heavy chain variable domain comprising (i) a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:4, (ii) a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:5, and (iii) a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:6.

[0131] In an alternative embodiment, the IgG1 antibody is an anti-CD20 antibody, e.g., an anti-CD20 monoclonal antibody. In an alternative embodiment, the IgG1 antibody is rituximab, or a biosimilar thereof. The term rituximab refers to a G1 kappa chimeric mouse / human monoclonal antibody that binds to the CD20 antigen, comprising the VH and VL, or VH-IgG1 and VL-IgG kappa sequences, as listed in Table 2, i.e., as set forth in SEQ ID NOs: 11-18, 23 or 24 (CAS No.: 174722-31-7; DrugBank-DB00073; see Kyoto Encyclopedia of Genes and Genomes (KEGG) entry D02994).

[0132] [Table 2]

[0133] The rituximab antibody, in some examples, comprises: (a) a light chain variable domain comprising (i) a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO: 11, (ii) a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO: 12, and (iii) a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO: 13; and (b) a heavy chain variable domain comprising (i) a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO: 14, (ii) a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO: 15, and (iii) a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO: 16.

[0134] Additional Process The methods disclosed herein include additional steps in various aspects. For example, in some aspects, the methods include one or more upstream or downstream steps involved in producing, purifying, and formulating the recombinant protein (e.g., an antibody). In an exemplary embodiment, the methods include a step for generating a host cell that expresses a recombinant glycosylated protein (e.g., an antibody). The host cell is, in some aspects, a prokaryotic host cell, such as E. coli or Bacillus subtilis, or the host cell is, in some aspects, a eukaryotic host cell, such as a yeast cell, a filamentous fungal cell, a protozoan cell, an insect cell, or a mammalian cell (e.g., a CHO cell). Such host cells are described in the art. See, e.g., Frenzel, et al., Front Immunol 4:217 (2013) and the "Cells" section herein. For example, the methods, in some examples, include introducing into the host cell a vector that includes a nucleic acid that includes a nucleotide sequence encoding the recombinant protein or a polypeptide chain thereof.

[0135] In exemplary embodiments, the methods disclosed herein include a step for isolating and / or purifying a recombinant protein (e.g., a recombinant antibody) from a culture. In exemplary aspects, the methods include one or more chromatography steps, including, but not limited to, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and / or hydrophobic interaction chromatography. In exemplary aspects, the methods include a step for producing a crystalline biomolecule from a solution containing the recombinant protein.

[0136] The methods of the disclosure, in various embodiments, include one or more steps for preparing compositions, such as, in some embodiments, pharmaceutical compositions that include the purified recombinant protein. Such compositions are described below.

[0137] composition Also provided herein are compositions comprising recombinant glycosylated proteins and antibodies produced by the methods described herein. In exemplary embodiments, the compositions are prepared by methods that modulate the amount of glycans (e.g., galactosylated glycans, terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) in the antibody. In exemplary aspects, the recombinant glycosylated protein is an antibody. Thus, provided herein are antibody compositions that include IgG1 antibodies (e.g., trastuzumab or rituximab antibodies) with increased or decreased ADCP activity, which have been engineered to have a particular ADCP activity, or increased or decreased ADCP activity compared to a control or reference antibody, by modulating (e.g., increasing or decreasing) the amount of glycans (e.g., galactosylated glycans, terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or a combination thereof) on the IgG1 antibody (e.g., trastuzumab or rituximab antibody).

[0138] In some embodiments, the compositions comprise an IgG1 antibody (e.g., a trastuzumab or rituximab antibody) produced by the methods described herein, which has increased or decreased ADCP activity compared to a reference IgG1 antibody (e.g., a trastuzumab or rituximab antibody), which has the same antibody sequence as the IgG1 antibody (e.g., a trastuzumab or rituximab antibody) with increased or decreased ADCP activity.

[0139] Thus, in exemplary embodiments, the antibody compositions of the present disclosure have increased ADCP activity to any degree or level as compared to a control or reference antibody. In exemplary examples, the increase in ADCP activity of the antibody compositions disclosed herein using the methods herein can be at least or about a 1% to about a 100% increase (e.g., at least or about a 1% increase, at least or about a 2% increase, at least or about a 3% increase, at least or about a 4% increase, at least or about a 5% increase, at least or about a 6% increase, at least or about a 7% increase, at least or about a 8% increase, at least or about a 9% increase, at least or about a 9.5% increase, at least or about a 9.8% increase, at least or about a 10% increase, at least or about a 20% increase, at least or about a 30% increase, at least or about a 40% increase, at least or about a 50% increase, at least or about a 60% increase, at least or about a 70% increase, at least or about a 80% increase, at least or about a 90% increase, at least or about a 90% increase, at least or about a 1 ... at least or about a 15% increase, at least or about a 20% increase, at least or about a 25% increase, at least or about a 30% increase, at least or about a 35% increase, at least or about a 40% increase, at least or about a 45% increase, at least or about a 50% increase, at least or about a 55% increase, at least or about a 60% increase, at least or about a 65% increase, at least or about a 70% increase, at least or about a 75% increase, at least or about a 80% increase, at least or about a 85% increase, at least or about a 90% increase, at least or about a 95% increase, at least or about a 100% increase). In exemplary embodiments, the increase in ADCP activity of the antibody compositions disclosed herein using the methods herein is greater than 100%, for example, at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to the level of a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is increased by at least about 1.5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is increased by at least about 2-fold compared to a control or reference antibody.In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by at least about 3-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by at least about 4-fold or about 5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is increased by an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0140] In alternative embodiments, the antibody compositions of the present disclosure have reduced ADCP activity to any degree or level compared to a control or reference antibody. For example, the reduction in ADCP activity of the antibody compositions disclosed herein using the methods herein can be at least or about 1% to about 100% (e.g., at least or about 1% reduction, at least or about 2% reduction, at least or about 3% reduction, at least or about 4% reduction, at least or about 5% reduction, at least or about 6% reduction, at least or about 7% reduction, at least or about 8% reduction, at least or about 9% reduction, at least or about 9.5% reduction, at least or about 9.8% reduction, at least or about 10% reduction, at least or about 15% reduction, at least or about 20% reduction, at least or about 25% reduction, at least or about 30% reduction, at least or about 35% reduction, at least or about 40% reduction, at least or about 50% reduction, at least or about 60% reduction, at least or about 70% reduction, at least or about 80% reduction, at least or about 90% reduction, at least or about 90% reduction, at least or about 90% reduction, at least or about 100% reduction, at least or about 150% reduction, at least or about 20% reduction, at least or about 30% reduction, at least or about 40% reduction, at least or about 50% reduction, at least or about 50% reduction, at least or about 60% reduction, at least or about 70% reduction, at least or about 80% reduction, at least or about 90% reduction, at least or about 90% reduction, at least or about 100% reduction, at least or about 150% reduction, at least or about 20% reduction, at least or about 30% reduction, at least or about 40% reduction, at least or about 50% reduction, at least or about 50% reduction, at least or about % reduction, at least or about a 20% reduction, at least or about a 25% reduction, at least or about a 30% reduction, at least or about a 35% reduction, at least or about a 40% reduction, at least or about a 45% reduction, at least or about a 50% reduction, at least or about a 55% reduction, at least or about a 60% reduction, at least or about a 65% reduction, at least or about a 70% reduction, at least or about a 75% reduction, at least or about a 80% reduction, at least or about a 85% reduction, at least or about a 90% reduction, at least or about a 95% reduction, at least or about a 100% reduction). In exemplary embodiments, the reduction in ADCP activity of the antibody compositions disclosed herein using the methods herein is greater than about 100%, for example, at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to the level of a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is reduced by at least about 1.5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising the same is reduced by at least about 2-fold compared to a control or reference antibody.In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by at least about 3-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by at least about 4-fold or at least about 5-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the level of ADCP activity of the antibody or composition comprising same is reduced by an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0141] In exemplary aspects, the antibody compositions of the disclosure include antibodies having an increased amount of glycans (e.g., galactosylated glycans, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) to any degree or level compared to a control or reference antibody. In illustrative examples, the antibody composition has an increased amount of glycans, which are increased by at least or about 1% to about 100% (e.g., at least or about 1%, at least or about 2%, at least or about 3%, at least or about 4%, at least or about 5%, at least or about 6%, at least or about 7%, at least or about 8%, at least or about 9%, at least or about 9.5%, at least or about 9.8%, at least or about 10%, at least or about 15%, at least or about 20%, at least or about 25%, at least or about 30%, at least or about 35%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 55%, at least or about 60%, at least or about 65%, at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 100%) compared to a control or reference antibody. In exemplary embodiments, the antibody composition has an increased amount of glycan, the glycan being increased by 100% or more, e.g., at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to a control or reference antibody. In exemplary embodiments, the antibody composition has an increased amount of glycan, the glycan being increased by at least about 1.5-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has an increased amount of glycan, the glycan being increased by at least about 2-fold compared to a control or reference antibody.In exemplary embodiments, the antibody composition has an increased amount of glycan, where the glycan is increased by at least about 3-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has an increased amount of glycan, where the glycan is increased by at least about 4-fold or about 5-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has an increased amount of glycan, where the glycan is increased by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has an increased amount of glycan, where the glycan is increased by an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0142] In exemplary aspects, the compositions of the disclosure include antibodies having an amount of glycans (e.g., galactosylated glycans, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or combinations thereof) that are reduced to any degree or level compared to a control or reference antibody. In illustrative examples, the antibody composition has a reduced amount of glycans, and the glycans are reduced by at least or about 1% to about 100% (e.g., at least or about 1%, at least or about 2%, at least or about 3%, at least or about 4%, at least or about 5%, at least or about 6%, at least or about 7%, at least or about 8%, at least or about 9%, at least or about 9.5%, at least or about 9.8%, at least or about 10%, at least or about 15%, at least or about 20%, at least or about 25%, at least or about 30%, at least or about 35%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 55%, at least or about 60%, at least or about 65%, at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 100%) compared to a control or reference antibody. In exemplary embodiments, the antibody composition has a reduced amount of glycans, the glycans being reduced by 100% or more, e.g., at least or about 125%, at least or about 150%, at least or about 175%, at least or about 200%, at least or about 300%, at least or about 400%, at least or about 500%, at least or about 600%, at least or about 700%, at least or about 800%, at least or about 900%, or even at least or about 1000%, compared to a control or reference antibody. In exemplary embodiments, the antibody composition has a reduced amount of glycans, the glycans being reduced by at least about 1.5-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has a reduced amount of glycans, the glycans being reduced by at least about 2-fold compared to a control or reference antibody.In exemplary embodiments, the antibody composition has a reduced amount of glycan, where the glycan is reduced by at least about 3-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has a reduced amount of glycan, where the glycan is reduced by at least about 4-fold or about 5-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has a reduced amount of glycan, where the glycan is reduced by at least about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a control or reference antibody. In exemplary embodiments, the antibody composition has a reduced amount of glycan, where the glycan is reduced by an amount in the range of about 0.5-fold to about 8-fold compared to a control or reference antibody.

[0143] In exemplary aspects, the antibody compositions of the disclosure comprise a total amount of glycans (e.g., galactosylated glycans, G1, G1a, G1b and / or G2 galactosylated species, non-fucosylated glycans, core fucose, high mannose glycans, M5 high mannose species, or a combination thereof) that is at least or about 0.5%, at least or about 1%, at least or about 2%, at least or about 3%, at least or about 5%, at least or about 7%, at least or about 10%, at least or about 15%, at least or about 20%, at least or about 25%, at least or about 30%, at least or about 35%, at least or about 40%, at least or about 4 ... 0%, at least or about 35%, at least or about 40%, at least or about 45%, at least or about 50%, at least or about 55%, at least or about 60%, at least or about 65%, at least or about 70%, at least or about 75%, at least or about 80%, at least or about 85%, at least or about 90%, at least or about 95%, at least or about 96%, at least or about 97%, or at least or about 98%, or the total amount of glycans is increased or decreased by at least or about 0.5% to 98%.

[0144] In exemplary embodiments, an antibody composition of the disclosure comprises a trastuzumab antibody that has an increased amount of terminal β-galactose or G1, G1a, G1b and / or G2 galactosylated species compared to a control or reference trastuzumab antibody and has increased ADCP activity compared to a control or reference trastuzumab antibody. In some embodiments, an antibody composition of the disclosure comprises a trastuzumab antibody, where about a 1 percent increase in the amount of terminal β-galactose or the amount of G1, G1a, G1b and / or G2 galactosylated species compared to a control or reference trastuzumab antibody results in about a 2.5, about 2.8, about 2.88, or about 3 percent increase in ADCP activity compared to the control or reference trastuzumab antibody.

[0145] In exemplary embodiments, antibody compositions of the disclosure comprise a trastuzumab antibody that has a reduced amount of terminal β-galactose or G1, G1a, G1b and / or G2 galactosylated species compared to a control or reference trastuzumab antibody and has reduced ADCP activity compared to a control or reference trastuzumab antibody. In some embodiments, an antibody composition of the disclosure comprises a trastuzumab antibody, wherein about a 1 percent decrease in the amount of terminal β-galactose or the amount of G1, G1a, G1b and / or G2 galactosylated species compared to a control or reference trastuzumab antibody results in about a 2.5, about 2.8, about 2.88, or about 3 percent decrease in ADCP activity compared to a control or reference trastuzumab antibody.

[0146] In exemplary embodiments, antibody compositions of the disclosure comprise a rituximab antibody that has reduced nonfucosylated glycans or increased amounts of core fucose compared to a control or reference rituximab antibody and has increased ADCP activity compared to a control or reference rituximab antibody. In some embodiments, an antibody composition of the disclosure comprises a rituximab antibody, wherein about a one percent reduction in nonfucosylated glycans or about a one percent increase in core fucose results in about a 0.5, about 0.7, about 0.75, about 0.8, or about 1 percent increase in ADCP activity compared to a control or reference rituximab antibody.

[0147] In exemplary embodiments, an antibody composition of the disclosure comprises a trastuzumab antibody that has an increased amount of nonfucosylated glycans or a decreased amount of core fucose compared to a control or reference trastuzumab antibody and has increased ADCP activity compared to a control or reference trastuzumab antibody. In some embodiments, an antibody composition of the disclosure comprises a trastuzumab antibody, wherein about a one percent increase in nonfucosylated glycans or about a one percent decrease in core fucose results in about a 0.5, about 0.56, about 0.6, or about 1 percent increase in ADCP activity compared to a control or reference trastuzumab antibody.

[0148] In exemplary embodiments, the antibody compositions of the disclosure comprise a trastuzumab antibody that has a reduced amount of nonfucosylated glycans or an increased amount of core fucose compared to a control or reference trastuzumab antibody and has reduced ADCP activity compared to a control or reference trastuzumab antibody. In some embodiments, the antibody compositions of the disclosure comprise a trastuzumab antibody, wherein about a one percent reduction in nonfucosylated glycans or about a one percent increase in core fucose results in about a 0.5, about 0.56, about 0.6, or about 1 percent reduction in ADCP activity compared to a control or reference trastuzumab antibody.

[0149] In exemplary embodiments, antibody compositions of the disclosure comprise a rituximab antibody that has an increased amount of nonfucosylated glycans or a decreased amount of core fucose compared to a control or reference rituximab antibody and has decreased ADCP activity compared to a control or reference rituximab antibody. In some embodiments, an antibody composition of the disclosure comprises a rituximab antibody, wherein about a 1 percent increase in nonfucosylated glycans or about a 1 percent decrease in core fucose results in about a 0.5, about 0.7, about 0.75, about 0.8, or about 1 percent decrease in ADCP activity compared to a control or reference rituximab antibody.

[0150] In exemplary embodiments, the antibody compositions of the disclosure include an IgG1 antibody (e.g., comprising trastuzumab or rituximab) that has an increased amount of high mannose glycans, e.g., including M5 high mannose species, compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab) and has decreased ADCP activity compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab). In some embodiments, the antibody compositions of the disclosure include an IgG1 antibody (e.g., comprising trastuzumab or rituximab) where an about 1 percent increase in high mannose glycans, e.g., including M5 high mannose species, results in a decrease in ADCP activity of about 1%, about 1.2%, about 1.31%, about 1.5%, about 1.7%, about 2%, about 2.11%, or about 2.5% compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab).

[0151] In exemplary embodiments, the antibody compositions of the disclosure include an IgG1 antibody (e.g., comprising trastuzumab or rituximab) that has a reduced amount of high mannose glycans, e.g., including M5 high mannose species, compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab) and has increased ADCP activity compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab). In some embodiments, the antibody compositions of the disclosure include an IgG1 antibody (e.g., comprising trastuzumab or rituximab) where about a one percent reduction in high mannose glycans, e.g., including M5 high mannose species, results in an increase in ADCP activity of about 1%, about 1.2%, about 1.31%, about 1.5%, about 1.7%, about 2%, about 2.11%, or about 2.5% compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab).

[0152] In some further exemplary embodiments, the antibody compositions of the disclosure comprise IgG1 antibodies (e.g., including trastuzumab or rituximab) that have increased or decreased amounts of a combination of galactosylated glycans (e.g., including terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species), non-fucosylated glycans or core fucose, and / or high mannose glycans (e.g., including M5 high mannose species). In an exemplary embodiment, the antibody composition comprises an IgG1 antibody (e.g., comprising trastuzumab or rituximab) that has (1) an increased amount of terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species, (2) a decreased amount of core fucose, or an increased amount of non-fucosylated species, and / or (3) a decreased amount of high mannose or M5 high mannose species, compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab), resulting in increased ADCP activity compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab). In some other exemplary embodiments, the antibody composition comprises an IgG1 antibody (e.g., comprising trastuzumab or rituximab) that has (1) a decreased amount of terminal β-galactose, or G1, G1a, G1b and / or G2 galactosylated species, (2) an increased amount of core fucose or a decreased amount of non-fucosylated species, and / or (3) an increased amount of high mannose or M5 high mannose species, compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab), resulting in decreased ADCP activity, compared to a control or reference IgG1 antibody (e.g., comprising trastuzumab or rituximab).

[0153] In an exemplary embodiment, the antibody compositions provided herein are combined with a pharma- ceutically acceptable carrier, diluent or excipient. Thus, provided herein is a pharmaceutical composition comprising a recombinant glycosylated protein composition (e.g., an antibody composition) described herein and a pharma- ceutically acceptable carrier, diluent or excipient. As used herein, the term "pharma- ceutically acceptable carrier" includes some of the standard pharmaceutical carriers, such as phosphate buffered saline, water, emulsions such as oil / water or water / oil emulsions, and various types of wetting agents.

[0154] The following examples are offered merely to illustrate the present disclosure and are not intended to limit its scope in any way. EXAMPLES

[0155] The following examples describe modulating ADCP effector function of IgG1 antibodies, including anti-HER2 and anti-CD20 antibodies, by increasing or decreasing specific glycans containing β-galactose, core fucose / non-fucosylated, and / or high mannose.

[0156] Introduction Therapeutic monoclonal antibodies, especially those of the IgG1 subclass, have effector function activities that may be important to their mechanism of action. One such effector function activity is antibody-dependent cellular phagocytosis (ADCP), which has been shown to be primarily mediated through the activating FcγR, FcγRIIa, of macrophages and neutrophils. The critical quality traits that most affect ADCP activity and are predictive and therefore best suited to monitor during the manufacture of IgG1 antibodies have not been well established. Primary cell assays for ADCP are often laborious and subject to donor-to-donor variability, making such assays less desirable for product characterization. By developing and using an ADCP reporter gene assay, we were able to sensitively determine glycan structures that may affect FcγRIIa-mediated ADCP across multiple different IgG1 mAbs. Interestingly, we observed that some IgG1 antibodies are very potent mediators of ADCP, whereas others do not mediate ADCP, despite having other effector function activities (ADCC and CDC). Furthermore, we found that different IgG1 mAbs have strikingly different sensitivity to ADCP glycan species, with one mAb showing a surprisingly strong effect of β-galactosylation and high mannose levels.

[0157] It has been confirmed that FcγRIIa-mediated ADCP may play a role in the mechanism of action (MoA) of some therapeutic Mabs. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology 2003; 21: 3940-7; Zhang W, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology 2007; 25: 3712-8. This realization has created a need for suitable in vitro assays with sufficient resolution and discrimination. One possible reason for the lack of a clear understanding of the influence of glycan structures in ADCP may be the problem of performing the necessary functional assays.Most published ADCP protocols use primary effector cells and fluorescent markers to track activity by flow cytometry (see, e.g., Petricevic B, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2 / neu breast cancer patients. Journal of translational medicine 2013;11:307). Such assays may show directional effects, but may have limited quantitative capabilities and lack reproducibility due to donor-to-donor variability and limited response levels. Additionally, while the use of primary cells may claim to provide a more physiologically meaningful assessment compared to cell line or receptor binding assays, they may not be sensitive or precise enough to reveal potential effector function activity. Recently, FcγRIIa reporter gene assays have been described, promising greatly simplified performance with high precision and accuracy. See Tada M, et al. Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PloS one 2014;9:e95787. We established a similar assay from a commercial source that utilizes a reporter gene cell line that responds to FcγRIIa binding. This assay is highly accurate, reproducible, and has good sensitivity to detect the contribution of various glycoforms. With the recognition that Fc glycan structures may require close process monitoring to control during the manufacturing process, a relatively high rate of heterogeneity may be encountered even in products from well-developed manufacturing processes.See Read EK, et al. Industry and regulatory experience of the glycosylation of monoclonal antibodies. Biotechnology and applied biochemistry 2011;58:213-9. Therefore, it is essential to establish a robust model for the contribution of different glycan structures and ADCP activity. Here, we describe the results of a genetically engineered ADCP assay combined with FcγR binding studies to characterize the impact of a wide range of glycan types and levels across many IgG1 monoclonal antibodies that exhibit effector functions.

[0158] In the examples below, the following methods were used:

[0159] Materials and Methods Sample preparation Humanized monoclonal IgG1 antibodies were expressed in CHO cells and produced at Amgen (Thousand Oaks, Calif.). The IgG1 antibodies ("mAbs") used in this study bind to membrane-expressed targets (CD20, HER2, or TNFα) and include trastuzumab (anti-HER2) and rituximab (anti-CD20).

[0160] Glycan species enrichment and enzymatic remodeling High mannose-containing species were enriched from the mAb using a ProSwift ConA-1S affinity column (5 x 50 mm, ThermoFisher, PN 074148) on an Agilent 1100 series HPLC system with a flow rate of 0.5 mL / min. The column was first kept at initial conditions with 100% buffer A (50 mM sodium acetate, 0.2 M NaCl, 1 mM CaCl2, 1 mM MgCl2, pH 5.3) for 10.5 min and then eluted with 100% buffer B (50 mM sodium acetate, 0.2 M NaCl, 1 mM CaCl2, 1 mM MgCl2, 100 mM α-methyl-mannopyranoside pH 5.3) for 17.5 min. Both the flow-through and elution fractions were collected and treated with β-(1-4)-galactosidase (QA Bio, PN E-BG07) to remove terminal galactose. Specifically, the mAb fraction was incubated with β-(1-4)-galactosidase at a ratio of 1 / 50 (μg / μg) in the presence of reaction buffer (pH 6.0) containing 50 mM sodium phosphate for 1 h at 37° C. The reaction was stopped by flash freezing.

[0161] Nonfucosylated species were prepared from mAbs by enzymatic treatment with Endo-H (QA-Bio, PN E-EH02). Specifically, mAbs were incubated with Endo-H for 24 h at 37 °C in a reaction buffer of 50 mM sodium phosphate (pH 5.5). The final mAb concentration was 4 mg / mL. Nonfucosylated mAbs were subsequently separated by affinity chromatography on an Agilent 1100 series HPLC using a customized glycap-3A column (low density FcγIIIa, 3 × 150 mm, Zepteon, PN R3AVD1P1ML). Mobile phase A contained 20 mM Tris, 150 mM NaCl (pH 7.5), and mobile phase B was 50 mM sodium citrate (pH 4.2). Both non-fucose-depleted (flow-through) and concentrated (eluted) mAbs were separated using a gradient (hold at 0% B for 8 min, 0% to 18% B for 22 min) at a flow rate of 0.5 mL / min, and enzymatic treatment with β-(1-4)-galactosidase was performed (as above) to remove any potential contribution of terminal galactose.

[0162] Galactose remodeling samples were generated by in vitro activity of β-1,4-galactosyltransferase (Sigma / Roche). First, fucosylated mAb (mainly G0F) was prepared by collecting the flow-through fraction from an FcγIIIa column and treated with galactosidase to remove terminal galactose. G0F enriched mAb was then incubated with β-1,4-galactosyltransferase at 37°C in a reaction buffer containing 10 mM UDP-galactose, 100 mM MES (pH 6.5), 20 mM MnCl2, and 0.02% sodium azide. The final enzyme to mAb ratio was 6 (μL / mg) and the mAb concentration was 2 mg / mL. MAbs with different levels of galactose were obtained by taking samples from the reaction mixture at various time points (10 min, 20 min, 30 min, 1 h, 2 h, 4 h, and 9 h) and then flash freezing to stop the reaction.

[0163] Protein A chromatographic purification was performed on all concentrated and remodeled samples to remove enzymes and other components. Purification was performed on an Agilent 1100 series HPLC system using a pre-packed Protein A column (Poros A / 20, 4.6 x 100 mm, Applied Biosystems, PN 1-5022-26) at a flow rate of 3 mL / min. After loading an appropriate amount of each sample, the column was first maintained at the initial conditions with 100% Buffer A (20 mM Tris-HCl / 150 mM NaCl, pH 7.0) for 1.4 min, and then eluted with 100% Buffer B (0.1% acetic acid) for 2.9 min. All eluted mAbs were diafiltered into formulation buffer using Amicon Ultra centrifugal filters with a 3 kDa cut-off membrane. Protein concentrations were typically around 1 mg / mL for all concentrated / remodeled mAb samples.

[0164] Characterization of glycan species enrichment and remodeling. All enriched and remodeled samples were characterized by hydrophilic interaction liquid chromatography (HILIC) and size-exclusion chromatography to ensure the desired glycan properties and minimal levels of high molecular weight species. Glycans from mAbs were released using PNGase F (New England BioLabs) at an E / S ratio of 1 / 25 (μL / μg) and labeled with 12 mg / mL 2-aminobenzoic acid (2-AA, Sigma-Aldrich) by incubating the reaction mixture at 80°C for 75 min. 2-AA labeled glycans were separated using a BEH glycan column (1.7 μm, 2.1 × 100 mm, Waters) on a Waters Acuity or H-Class UPLC system equipped with a fluorescence detector. The column temperature was maintained at 55°C. Mobile phase A contained 100 mM ammonium formate (pH 3.0) and mobile phase B was 100% acetonitrile. Glycans were bound to the column in high organic solvent and then eluted with an increasing gradient of aqueous ammonium formate buffer (76% B held for 5 min, followed by elution with a gradient from 76% B to 65.5% B over 14 min). Verification that the required procedures did not result in the formation of high molecular weight species was assessed using a size exclusion column (SEC) TSK-Gel G3000SWLXL (7.8 x 300 mm, Tosoh Bioscience) on an Agilent 1100 HPLC system at a flow rate of 0.5 mL / min. Sample loads of 20-40 μg of sample were typically separated isocratically using a mobile phase containing 100 mM sodium phosphate (pH 6.8) and 250 mM NaCl.

[0165] ADCP assay The ADCP luciferase reporter gene assay uses genetically engineered Jurkat T cells as effector cells. Jurkat reporter cells express FcγRIIa-(H131 variant) on the cell surface as well as a luciferase reporter gene with response elements for factor for T cell activator (NFAT). These cells were modified from Promega catalog number G9901. Simultaneous binding between antibody bound to target cells and antibody bound to FcγRIIa on Jurkat effector cells activates the transcription factor NFAT. Activated NFAT translocates into the nucleus of Jurkat cells and induces luciferase reporter gene expression. Addition of a luciferase substrate containing luciferin and detergent generates a luminescent signal, allowing detection of ADCP reporter activity. For anti-CD20 antibodies, reference standards, assay controls, and test samples were serially diluted across eight concentration levels to final plate well concentrations ranging from 1.76 to 600 ng / mL in RPMI1640 assay medium with low IgG FBS to generate dose-response curves. Effector Jurkat reporter cells and target (CD20+Raji) cells were mixed at an effector to target (E to T) cell ratio of 3:2 to prepare cell suspensions. Plates were then incubated for 5.5 hours in a humidified incubator at 5% CO2 and 37°C. At the end of the incubation, cells were lysed by detergent in luciferase assay buffer. Luciferase catalyzes the emission of its substrate luciferin, which was detected by an EnVision plate reader. Data were fitted to mean luminescence values ​​using a four-parameter curve fit in SoftMax Pro 7 and reported as percent relative activity (EC50 standard / EC50 sample) for each run of a typical bioassay. Each sample was tested in three independent assays and the final result for a sample is reported as the average of the triplicate determinations. Anti-TNFα antibody assays were performed similarly but using a dose range of 234.4-30,000 ng / mL and a CHO target cell line engineered to express uncleaved TNFα on its cell surface15.ADCP assays for anti-HER2 antibodies were performed similarly, but with a dose response range of 31.3-4000ng / mL, using the HER2+SKOV-3 cell line as target cells. Incubation of plates at 5% CO2 and 37°C is approximately 6.5 hours to achieve higher luciferase response. Activity of anti-HER2 antibodies was calculated by fitting dose response data to a 4-parameter curve similar to other molecules, but relative activity was calculated without SoftMax Pro, using the following empirically derived formula: Relative Potency = (B sample / B reference)E x (C reference / C sample) x (D sample / D reference)F. The B ratio (B sample / B reference) was obtained by dividing the Hill slope of the reference standard by the Hill slope of the sample. The C ratio (C reference / C sample) was obtained by dividing the EC50 of the reference standard by the EC50 of the sample value. The D ratio (D sample / D reference) was obtained by dividing the upper asymptote of the reference standard by the upper asymptote of the sample value. If B sample / B reference ≧1.0 and C reference / C sample ≧1.0, E=0.05; if B sample / B reference ≧1.0 and C reference / C sample <1.0, E=0.20; if B sample / B reference <1.0, E=0.15; if D reference / D sample >1.0, F=1.8×(D reference / D sample)(0.45×(D reference / D sample)^0.35); if D reference / D sample ≦1.0, F=1.8×(D sample / D reference)(1.45×(D reference / D sample)^1.75). This formula took into account the fact that B, C and D values ​​are all affected by the quality attributes in this assay.

[0166] FcγRIIa binding. The relative binding activity of antibody samples to FcγRIIa was measured with a competitive amplified luminescent proximity homogeneous assay (AlphaLISA™, Perkin Elmer). The assay contains two bead types, acceptor beads and donor beads. The acceptor beads contain glutathione, which binds to recombinant human FcγRIIa-glutathione-S-transferase (FcγRIIa GST) prepared in-house. The donor beads are coated with streptavidin, which binds to biotinylated human IgG1 prepared in-house and serves as a competitor for the samples. When FcγRIIa GST and biotinylated human IgG1 bind, they bring the acceptor and donor beads into close proximity. When the complex is illuminated with a laser, ambient oxygen is converted to singlet oxygen by the donor beads, resulting in light emission measured at 570 nm. When the sample is present at a concentration sufficient to inhibit the binding of FcγRIIa GST to biotinylated human IgG1, a dose-dependent decrease in luminescence is measured. The binding assay was performed in a 96-well AlphaPlate (PerkinElmer). Glutathione-coated acceptor beads were coated with human Fc gamma RIIa-GST-H6 and prepared in AlphaLISA immunoassay buffer to a final concentration of 25 μg / mL and 5 nM, respectively. The mixture is incubated for 2-4 hours at room temperature in the dark (the beads are light-sensitive). The reference standard, control and sample substances are serially diluted 2.5-fold from 100 nM to 0.164 nM (PerkinElmer) in AlphaLISA™ immunoassay buffer in the dilution plate and 90 μL of each well is transferred to a fresh mixing plate. Biotinylated IgG1 competitor is prepared in immunoassay buffer to a final concentration of 2 nM. 90 μL of biotinylated IgG1 competitor was added to all wells of the mixing plate from low to high concentration. Each well was mixed at least 5 times by pipetting up and down, then 40 μL was transferred to each appropriate well of the triplicate assay plate. After the 2 hour incubation of glutathione receptor beads and FcγRIIa was completed, 40 μL of the mixture was added to each well of the assay plate.Plates were sealed and placed on a shaker for 2 minutes and then incubated at room temperature in the dark for 22-26 hours. After incubation, streptavidin donor beads were diluted in immunoassay buffer to a final concentration of 50 μg / mL and 20 μL was added to each well of the assay plate for a total reaction volume of 100 μL. Plates were resealed, placed on a shaker for 2 minutes and incubated at room temperature in the dark for 2-6 hours. After incubation, the plate sealer was removed and plates were read on an Envision at 680 nm excitation and 570 nm emission. Binding of test samples relative to the reference standard was measured and reported as percent relative binding. Each data point of the dilution curve was run in triplicate on three assay plates. The data was fitted to the mean emission values ​​using a four-parameter curve fit with SoftMax Pro 7 and IC50 standard / IC50 sample was calculated and reported as percent activity. Each sample was tested in three independent assays and final sample results were reported as the average of triplicate determinations.

[0167] Antigen binding CD20 antigen binding assays were performed using WIL2-S cells, a human β-lymphoblastoid cell line, utilizing a competitive assay format that reports fluorescence inhibition. Test samples compete with a fixed concentration of an Alexa-488-labeled form of the reference standard for binding to cell surface-expressed CD20 on WIL2-S cells. Dose-response curves of the reference standard, assay control, and test samples were generated by serial dilution across eight concentrations to a final concentration range of 4.92-3000 ng / mL in PBS containing 0.5 mg / mL BSA. Alexa-488-labeled competitors were diluted to a final in-well concentration of 100 ng / mL. Samples, competitors, and WIL2-S cells diluted to 30,000 cells / well were added in duplicate to a 96-well plate and sealed with a plate sealer. Plates were then incubated at room temperature for 4.5-6 hours before measuring the fluorescent signal on an Acumen® eX3 Imaging Cytometer (TTP Labtech). A dose-dependent decrease in the fluorescent signal was detected with increasing concentrations of the test samples. Relative CD20 binding of test samples to the reference standard sample was reported. Data were fitted to mean luminescence values ​​using a four-parameter curve fit with SoftMax Pro 7 and IC50 standard / IC50 sample was calculated and reported as percent relative binding activity. Each sample was tested in three independent assays and the final result for a sample was reported as the average of triplicate determinations. HER2 binding assays were performed in a similar manner, except that HER2-positive SKBR-3 were used as target cells and the dose-response curve ranged from (0.016 to 10 μg / mL).

[0168] Example 1 Evaluation of ADCP activity of anti-HER2, anti-CD20 and anti-TNFα IgG1 antibodies An evaluation of potential ADCP activity for a series of human IgG1 monoclonal antibodies against cell surface antigens was performed using an ADCP reporter gene assay (see Materials and Methods above for details). The antibodies evaluated showed a range of activity in this assay. An overlay of dose-response curves for three different IgG1 mAbs, representing a range of activity, is shown in Figure 2. The anti-TNFα antibody showed virtually no response, even though it was evaluated at the highest concentration range tested for all antibodies. In contrast, the anti-CD20 antibody showed a very strong response at a relatively low concentration range, reaching maximum stimulation at a fraction of 20-fold. The anti-HER2 antibody showed an intermediate response. All three of these antibodies mediate ADCC against these same target cell lines, as measured in an in vitro ADCC activity assay (data not shown). The observation that ADCP activity against two different targets was obtained by two different antibodies led to a more detailed study of this assay and the properties that influence these activities.

[0169] As a first step, to demonstrate the quantitative nature and range of the ADCP reporter gene assay and therefore its suitability for the assessment of quality attributes that affect ADCP activity, linear assays were performed using simulated activity or potency levels with concentration adjustments. Figures 3A-D show the results of predicted and observed ADCP activity values ​​for both anti-CD20 (Figures 3A-B) and anti-HER2 (Figures 3C-D) antibodies, with respective dose-response curves (see Figures 3B and 3D) and correlation graphs (see Figures 3A and 3C).

[0170] Using the quantitative range of the assay established from 25% to 250% relative ADCP activity, we next investigated the quality attributes related to the conserved N-linked glycans in the Fc domain of two active mAbs (anti-CD20 and anti-HER2). Samples of each antibody were prepared to evaluate various high mannose, beta-galactose and fucose structures as shown in Figure 4.

[0171] Antibody samples bearing each of the various major glycan types were prepared as described. The effect of each glycan on the relative ADCP activity is detailed in the following section.

[0172] Example 2 Effect of terminal β-galactose on the ADCP activity of anti-HER2 and anti-CD20 IgG1 antibodies The first glycan species examined was β-galactose. The anti-HER2 antibody showed a very strong response to various β-galactoses. The dose-response curves of galactosylation are shown in Figure 5. In addition to producing quantitatively very different activity levels, there was also a qualitative change in the shape of the dose-response curve to β-galactose levels, with the Hill slope and Emax decreasing with decreasing β-galactose levels. See Materials and Methods above for an explanation of the calculation of relative activity.

[0173] The calculated activity yielded a highly linear response to the glycan (Figure 6). We were also able to quantify the relative impact of β-galactose on ADCP activity by expressing it in terms of the slope of the activity / property correlation plot, which can be considered to represent the response factor. Using this approach in an anti-HER2 antibody, the ADCP impact can be calculated to be 2.88 with β-galactose.

[0174] Surprisingly, when the same analysis was performed for anti-CD20 antibodies, the response to β-galactose levels was found to be virtually unchanged, as shown in Figure 7. For anti-CD20 antibodies, the observed effects were minimal between the lowest and highest achievable levels of β-galactose, so intermediate levels were not tested.

[0175] As an additional measure of the responsiveness of the ADCP reporter gene assay to glycan levels, an FcγRIIa binding assay using the AlphaLISA format was performed to orthogonally evaluate the effect of β-galactose on anti-HER2 antibodies. The FcγRIIa binding assay was qualified to cover a similar broad range of binding activity as the linear approach used in the ADCP assay (data not shown). As can be seen in Figure 8, there was a linear response to β-galactose levels in a subset of samples covering the same range of β-galactose. It is interesting to note that the magnitude of the response of the AlphaLISA binding assay was much milder than that generated by the ADCP assay. The slope of the plot of relative FcγRIIa binding as a function of β-galactose levels was only 0.33, compared to the 3.05 response factor in Figure 6, which is about a 9-fold stronger response rate than the ADCP assay.

[0176] As a control for possible antigen binding impacts as a result of glycoengineering procedures, graphs of relative antigen binding activity for representative samples across a range of β-galactose levels are shown in Figures 9A-B. From these results, it can be concluded that the differences in relative ADCP activity can be attributed to differences in FcγRIIa binding and not to unexpected changes in cell surface target binding.

[0177] Example 3 Effect of core fucose / non-fucosylation on ADCP activity of IgG1 antibodies The response to fucosylation (in the form of non-fucosylated [lack of fucose] levels) is shown in Figures 10A-B. Although less dramatic than the response to β-galactose, a linear increase in ADCP activity to the anti-HER2 antibody was observed, with a response factor of 0.56. Figure 10A. The anti-CD20 antibody showed a small but linear decrease in ADCP activity with increasing non-fucosylation. Figure 10B. The negative slope is very shallow, but is discernible and reproducible given the precision of the method.

[0178] Example 4 Effect of high mannose on ADCP activity of IgG1 antibodies The response of anti-HER2 antibodies to high mannose was somewhat complicated by the inability to completely separate lower-level high mannose species from higher-level high mannose species by affinity chromatography methods, and also by not bringing in the different β-galactose levels associated with the samples. Typically, β-galactose is removed for this evaluation, allowing for evaluation of the effect due solely to differences in high mannose. However, as shown in Example 2, removal of β-galactose abolishes activity. Thus, to evaluate the effect of high mannose on the ADCP activity of anti-HER2 antibodies, two sets of samples were compared. The first set ranged from 1% to 91% as discussed in Example 2, but all had the same β-galactose levels with a common level of high mannose (approximately 2%). The second set included samples ranging from 17% β-galactose to 36% β-galactose (an intermediate level was achieved by blending the two), but also included high mannose ranging from 1.6% to 52%. The ADCP activity to β-galactose from each reported set is plotted in Figure 11A-B. It was observed that the sets containing high mannose ranging from 1.2 to 52% all showed lower ADCP activity compared to the set with high mannose fixed at 2%, indicating that high mannose has a negative impact on ADCP activity for anti-HER2 antibodies. Figure 11A. The same analysis was performed using FcγRIIa binding assay and is shown in Figure 11B. The slopes of the sample sets containing various high mannose are also affected by the range of β-galactose present in these samples, so the slope values ​​cannot be considered as response factors for high mannose as for other glycan properties. Rather, knowing the relationship between β-galactose and high mannose for these samples, and the relationship between β-galactose and ADCP activity, the response factors for high mannose could be calculated to be -2.11 for ADCP activity and -0.81 for the binding assay.

[0179] The calculation to determine the response factor for high mannose in the ADCP assay was as follows: Relative ADCP activity % as a function of β-galactose % y=5.4379x-100.1 x=(y+100.1) / 5.4379(1) The formula for % β-galactose to % mannose is rewritten in terms of z, where z is the % mannose level. y=-0.3881x+36.961 x=-0.3881z+36.961(2) Next, (2) is substituted into (1) to obtain the equation for y (% relative FcγRIIa binding) in terms of z (% mannose level) x=-0.3881z+36.961 (y+100.1) / 5.4379=-0.3881z+36.961

number

[0180] The calculation to determine the response factor for high mannose in the FcγRIIa binding assay was as follows: Relative FcγRIIa binding % as a function of β-galactose % y=2.0759x+25.805 x=(y-25.805) / 2.0759(1) The formula for % β-galactose to % mannose is rewritten in terms of z, where z is the % mannose level. y=-0.3881x+36.961 x=-0.3881z+36.961(2) Next, (2) is substituted into (1) to obtain the equation for y (% relative FcγRIIa binding) in terms of z (% mannose level) x=-0.3881z+36.961 (y-25.805) / 2.0759=-0.3881z+36.961

number

[0181] Samples for evaluation of high mannose on anti-CD20 antibodies were easier to manipulate, as β-galactose does not significantly affect ADCP activity. Similar to what was found for fucosylation, anti-CD20 antibodies show a slight linear decrease in ADCP activity with increasing high mannose levels, as shown in Figure 12A. Also shown in Figure 12B is the corresponding FcγRIIa AlphaLISA binding assay, which shows a negative correlation, similar to high mannose. Again, the ADCP assay shows a slightly larger glycan effect than the orthogonal binding assay.

[0182] Consideration A summary of the effect of different glycan species on ADCP activity, as measured by response factors for CD20 and HER2 antibodies, is summarized in Table 3. When the amount of a particular glycan (non-fucose, high mannose or terminal β-galactose) was increased in each antibody, either an increase in ADCP activity (indicated by a positive number in Table 3) or a decrease in ADCP activity (indicated by a negative number in Table 3) was observed.

[0183] [Table 3]

[0184] In the production of therapeutic antibodies, it is important to identify and characterize all of the effector function activities that the molecule can mediate. While ADCC and CDC assays are well established, ADCP is often overlooked as a possible mechanism of activity and action due to the more limited sensitivity and range of assays required, and the quality attributes that influence activity are less understood. However, ADCP has been suggested as a possible mechanism of action for at least two currently marketed therapeutic monoclonal antibodies (Kim S, et al. Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar. mAbs 2017;9:704-14, and Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. Journal of clinical oncology: Official journal of the American Society of Clinical Oncology 2003;21:3940-7), so it is crucial to monitor critical quality attributes that may affect ADCP activity. Indeed, for molecules that exhibit any of these activities, it will be essential to elucidate these structure / function relationships to ensure adequate process control and for the demonstration of analytical similarity in the development of biosimilars. Central to achieving this objective is the development of functional assays that are sensitive to changes in quality attributes that may change as part of the manufacturing process. In this study, material was generated from two representative therapeutic monoclonal antibodies produced in a CHO production process using a combined enzymatic modification and enrichment process to yield three major glycan species with a wide range of isolation, respectively.The inventors were able to achieve a substantially wider range than would be possible by adjusting process parameters to find more precisely the relationship between glycan species and effector activity.

[0185] The nature of the interactions between IgG antibody Fc domains and Fcγ receptor family members has been extensively reviewed in Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 2015;25:1325-34. The role of conserved glycans and various structural forms has been well established by binding and functional studies on FcγRIIIa and ADCC, but the influence of glycan structure on FcγRIIa and ADCP is less clear. Most studies have not found a substantial relationship between the structure of conserved N-linked glycans and FcγRIIa binding and ADCP, although a few reports do observe a correlation. Chung et al. (see Chung S, et al. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. mAbs 2012;4:326-40) found that for anti-CD20 antibodies, there was a trend for increased FcγRIIa binding with increasing levels of defucosylation from 0 to 100%. These data were obtained by testing mixed samples from DP12 (wild type producing) and FUT8-deficient (non-fucosylated) CHO cell lines in an ELISA binding assay. In a reporter gene ADCP assay, we observed a slight increase in anti-HER2 antibodies with increasing levels of defucosylation, whereas anti-CD20 antibodies instead showed a slight decrease in activity. Differences in assay format and the fact that Chung et al. used the 131R allotype for binding studies, whereas the present study used the 131H allotype, may have contributed to the different observations. The results may also be influenced by the possibility that different anti-CD20 molecules were used in these studies, as well as the possibility that there may be other structural differences derived from the FUT8-deficient host that were not accounted for by the in vitro engineering process used in this study.Of note, another study (Golay J, et al. Glycoengineered CD20 antibody Obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013;122:3482-91) used an anti-CD20 antibody that was glycoengineered by production in a CHO line with inducible N-acetylglucosaminyltransferase III (GntIII) expression, resulting in bisected glycans that are not substrates for fucosyltransferases and are therefore expressed predominantly in the nonfucosylated form. See Umana P, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody -dependent cellular cytotoxic activity. Nature biotechnology 1999;17:176-80. In that study, the authors observed virtually no effect of fucose levels on FcγRIIa binding to the 131R allotype, but a slight decrease in binding to the 131H allotype as measured by surface plasmon resonance, which would be consistent with our study. Recent studies have confirmed that galactose levels have an effect (see Chung AW et al. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. Aids 2014;28:2523-30). In this study, the authors were able to observe an increase in human macrophage cell line ADCP assays and FcγRIIa binding SPR binding assays for antibodies containing high levels of terminal sugars such as galactose.Unique to these experiments, all glycan species were predominantly α-linked rather than β-linked as used in this study, and were present on various mouse monoclonal antibodies present on the much more commonly used CHO host cell line. Another study looked at the effect of galactose levels on the binding of mouse monoclonals to FcγRIIb, a receptor structurally related to FcγRIIa (see Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature reviews Immunology 2004;4:89-99), but with an inhibitory intracellular signaling motif. In several in vivo assays of neutrophil activity thought to be mediated by FcγRIIa, these authors observed that the enzymatically fully galactosylated form of the molecule had much higher activity than the enzymatically fully degalactosylated form. Karsten CM et al.Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1.Nature medicine 2012;18:1401-6. Thus, efforts have been made to explore the influence of glycan structure on FcγRIIa binding and signaling activity, and this report appears to be the first effort to systematically evaluate many different glycan species in a cell-based assay for FcγRIIa binding.

[0186] Perhaps the greatest challenge in studying the structural determinants of ADCP activity has been the reliance on primary effector cells that are susceptible to donor-to-donor response variability, as well as receptor allotypic differences and other underlying genetic and phenotypic changes that can affect assay output. Also, as described elsewhere, it is generally more difficult to identify the receptor associated with ADCP on phagocytes, since many different FcγR types can be expressed on the effector cells of interest. See Ackerman ME,et al.A robust,high-throughput assay to determine the phagocytic activity of clinical antibody samples.Journal of immunological methods 2011;366:8-19. Therefore, the limitations of these types of assays in drug development and their characterization in a quality control setting should be recognized. To circumvent these challenges, Tada et al. (Tada M, et al. Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PloS one 2014;9:e95787) developed a reporter gene assay for FcγRIIa-mediated ADCP. This assay overcomes many of the limitations mentioned above. In addition to demonstrating the usefulness and convenience of using a reporter gene assay for ADCP activity, they found that the methionine oxidation of cetuximab affects ADCP activity.

[0187] Using a similar assay method, we report for the first time that common glycoforms can have a substantial and differential effect on ADCP activity among IgG1 mAbs. Most striking is the effect of β-galactose on the anti-HER2 antibody. A 10-fold change in activity was observed even when the range of terminal β-galactose levels was limited to those observed during typical manufacturing processes. Interestingly, an effect of similar magnitude but in the opposite direction (reduced with increasing levels) was found for high mannose on this antibody. Such results could provide a control strategy for any such molecule where ADCP is part of the proposed mechanism of action. Interestingly, no substantial effect was observed for the anti-CD20 antibody with a similar wide range of terminal β-galactose levels. In contrast, for the same molecule, the effect of non-fucosylation and high mannose is the opposite of what is generally expected for FcγRIIIa binding and ADCC. The structural basis for the effect of these glycans on ADCC was revealed from the co-crystal structure of FcgRIIIa with the IgG1 Fc domain. See Ferrara C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proceedings of the National Academy of Sciences of the United States of America 2011;108:12669-74. Similar structural studies of FcγRIIa binding may be similarly revealing if performed.

[0188] As a final observation, the results presented here indicate that if a glycan effect is observed, the magnitude of the response may be greater than that reported by the orthogonal AlphaLISA binding assay, which itself is generally more responsive than SPR or ELISA assay formats to binding differences. See Xu Z, et al. Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation. Journal of immunology 2012;189:4470-7. The responsiveness seen with this ADCP assay may be unique, given that reports of ADCC impact characterization utilizing both cell-based and binding assays have found more responsiveness in binding assays than in cell-based activity assays. See Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 2015;25:1325-34. See also Chung S, et al. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibody-impact of effector cells. Journal of immunological methods 2014;407:63-75. This fact further highlights the potential sensitivity and utility of this assay for FcγRIIa binding.

[0189] In conclusion, not all IgG1 mAbs directed to cell surface targets have the same ability to induce all effector functions, and quality attributes may have differential impact on different effector functions, if activity is present. This highlights the importance of carefully assessing ADCP activity as well as ADCC and CDC activity assessments, and controlling relevant critical quality attributes in the manufacturing process. It also highlights the need to establish appropriate controls on a case-by-case basis, as platform control strategies may not be adequate. To this end, we highlight the value of having high-resolution assays with high-throughput potential that can reveal CQAs related to effector functions that might otherwise have been overlooked. Although the desire to pursue physiologically relevant assays may lead to a reliance on primary cells, the best approach may be to apply a combination of primary cell assays that provide a physiological context for hypothesis testing, and robust, sensitive, and high-throughput reporter gene assays that establish production parameters.

[0190] References 1. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al.Advances in the assessment and control of the effector functions of therapeutic antibodies.Nature reviews Drug discovery 2011;10:101-11. 2. Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 2015;25:1325-34. 3. Okazaki A,Shoji-Hosaka E,Nakamura K,Wakitani M,Uchida K,Kakita S,et al.Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.Journal of molecular biology 2004;336:1239-49. 4. Ferrara C,Grau S,Jager C,Sondermann P,Brunker P,Waldhauer I,et al.Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.Proceedings of the National Academy of Sciences of the United States of America 2011;108:12669-74. 5. Thomann M,Reckermann K,Reusch D,Prasser J,Tejada ML.Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.Molecular immunology 2016;73:69-75. 6. Hodoniczky J,Zheng YZ,James DC.Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.Biotechnology progress 2005;21:1644-52. 7. Shinkawa T,Nakamura K,Yamane N,Shoji-Hosaka E,Kanda Y,Sakurada M,et al.The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.The Journal of biological chemistry 2003;278:3466-73. 8. Umana P,Jean-Mairet J,Moudry R,Amstutz H,Bailey JE.Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity.Nature biotechnology 1999;17:176-80. 9. Kim S,Song J,Park S,Ham S,Paek K,Kang M,et al.Drifts in ADCC-related quality attributes of Herceptin(R):Impact on development of a trastuzumab biosimilar.mAbs 2017;9:704-14. 10. Weng WK,Levy R.Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.Journal of clinical oncology :official journal of the American Society of Clinical Oncology 2003;21:3940-7. 11. Zhang W,Gordon M,Schultheis AM,Yang DY,Nagashima F,Azuma M,et al.FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.Journal of clinical oncology :official journal of the American Society of Clinical Oncology 2007;25:3712-8. 12. Petricevic B,Laengle J,Singer J,Sachet M,Fazekas J,Steger G,et al.Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2 / neu breast cancer patients.Journal of translational medicine 2013;11:307. 13. Tada M,Ishii-Watabe A,Suzuki T,Kawasaki N.Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies.PloS one 2014;9:e95787. 14. Read EK,Park JT,Brorson KA.Industry and regulatory experience of the glycosylation of monoclonal antibodies.Biotechnology and applied biochemistry 2011;58:213-9. 15. Arora T,Padaki R,Liu L,Hamburger AE,Ellison AR,Stevens SR,et al.Differences in binding and effector functions between classes of TNF antagonists.Cytokine 2009;45:124-31. 16. Chung S,Quarmby V,Gao X,Ying Y,Lin L,Reed C,et al.Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities.mAbs 2012;4:326-40. 17. Golay J,Da Roit F,Bologna L,Ferrara C,Leusen JH,Rambaldi A,et al.Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.Blood 2013;122:3482-91. 18. Chung AW,Crispin M,Pritchard L,Robinson H,Gorny MK,Yu X,et al.Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.Aids 2014;28:2523-30. 19. Woof JM,Burton DR.Human antibody-Fc receptor interactions illuminated by crystal structures.Nature reviews Immunology 2004;4:89-99. 20. Karsten CM,Pandey MK,Figge J,Kilchenstein R,Taylor PR,Rosas M,et al.Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1.Nature medicine 2012;18:1401-6. 21. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. Journal of immunological methods 2011;366:8-19. 22. Xu Z, Juan V, Ivanov A, Ma Z, Polakoff D, Powers DB, et al.Affinity and cross-reactivity engineering of CTLA4-Ig to modulate T cell costimulation.Journal of immunology 2012;189:4470-7. 23. Chung S, Lin YL, Reed C, Ng C, Cheng ZJ, Malavasi F, et al.Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.Journal of immunological methods 2014;407:63-75.

[0191] All publications, patents, and patent applications cited herein are incorporated by reference as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. Although the above invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those skilled in the art in light of the teachings of the present disclosure that certain changes and modifications can be made thereto without departing from the spirit or scope of the disclosed embodiments. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.

[0192] The recitation of ranges of values ​​herein, unless otherwise stated herein, is merely intended to serve as a shorthand method of referring individually to each of the separate values ​​within that range, and each of the endpoints, and each separate value and endpoint is incorporated herein as if it were individually set forth herein.

[0193] All methods described herein can be performed in any suitable order unless otherwise indicated herein or clearly contradicted by context. The use of any examples or exemplary language (e.g., "etc.") provided herein is merely intended to further clarify the disclosure and does not impose limitations on the scope of the disclosure unless otherwise asserted. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.

[0194] Preferred embodiments of the disclosure are described herein, including the best mode known to the inventors for carrying out the disclosure. Variations of these preferred embodiments will become apparent to those skilled in the art upon reading the above description. The inventors expect that those skilled in the art will adopt such variations as necessary, and the inventors intend for the disclosure to be practiced in other forms than those specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by this disclosure unless otherwise indicated herein or clearly contradicted by context.

Claims

1. A method of modulating antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab, comprising increasing or decreasing the amount of terminal β-galactose in the antibody, or increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody.

2. 1. A method of increasing antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab, comprising increasing the amount of terminal β-galactose in the antibody or increasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody.

3. 3. The method of claim 1 or 2, wherein about a 1 percent increase in β-galactose increases ADCP activity by about 2.5, about 2.8, about 2.88, or about 3 percent.

4. 1. A method of decreasing antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab, comprising decreasing the amount of terminal β-galactose in the antibody or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody.

5. 5. The method of claim 1 or 4, wherein about a 1 percent reduction in β-galactose reduces ADCP activity by about 2.5, about 2.8, about 2.88, or about 3 percent.

6. A method for matching the antibody-dependent cellular phagocytosis (ADCP) activity of a reference trastuzumab antibody, comprising the steps of: (1) determining the ADCP activity of the reference trastuzumab antibody; (2) determining the ADCP activity of a second antibody having the same antibody sequence as the reference trastuzumab antibody; and (3) increasing or decreasing the amount of terminal β-galactose in the second antibody, or increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species in the second antibody. wherein the ADCP activity of said second antibody after increasing or decreasing the amount of terminal β-galactose, or after increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species, is the same as, or within about 10%, 15%, 20%, 25%, 30%, or 35% of, said reference antibody, or within the range of about 1% to about 35% of said reference antibody.

7. 7. The method of claim 6, wherein the ADCP activity of the second antibody is increased by increasing the amount of terminal β-galactose in the second antibody or by increasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the second antibody, and wherein the ADCP activity of the second antibody after increasing the ADCP activity is the same as that of the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

8. 7. The method of claim 6, wherein the ADCP activity of the second antibody is reduced by decreasing the amount of terminal β-galactose in the second antibody or by decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species in the second antibody, and wherein the ADCP activity of the second antibody after reducing the ADCP activity is the same as that of the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

9. 1. A method of manipulating a specific target antibody-dependent cellular phagocytosis (ADCP) activity of a trastuzumab antibody, comprising the steps of: (1) determining an ADCP activity of the trastuzumab antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the antibody by increasing or decreasing the amount of terminal β-galactose in the antibody, or increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of terminal β-galactose, or after increasing or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species, is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity.

10. A method for modulating the antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab or rituximab, comprising increasing or decreasing the amount of core fucose in the antibody, or increasing or decreasing the amount of fucosylated species in the antibody.

11. A method for increasing antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab, comprising decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species of the antibody.

12. 12. The method of claim 10 or 11, wherein about a 1 percent reduction in core fucose increases the ADCP activity of the trastuzumab antibody by about 0.5, about 0.56, about 0.6 or about 1 percent.

13. A method for increasing antibody-dependent cellular phagocytosis (ADCP) activity of rituximab, comprising increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody.

14. 14. The method of claim 10 or 13, wherein an increase of about 1 percent in core fucose increases the ADCP activity of rituximab by about 0.5, about 0.7, about 0.75, about 0.8 or about 1 percent.

15. A method for reducing antibody-dependent cellular phagocytosis (ADCP) activity of trastuzumab, comprising increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody.

16. 16. The method of claim 10 or 15, wherein an increase of about 1 percent in core fucose decreases the ADCP activity of the trastuzumab antibody by about 0.5, about 0.56, about 0.6 or about 1 percent.

17. 1. A method of reducing antibody-dependent cellular phagocytosis (ADCP) activity of rituximab, comprising decreasing the amount of core fucose in the antibody or increasing the amount of non-fucosylated species of the antibody.

18. 20. The method of claim 10 or 17, wherein about 1 percent reduction in core fucose reduces the ADCP activity of rituximab by about 0.5, about 0.7, about 0.75, about 0.8 or about 1 percent.

19. 1. A method for matching antibody-dependent cellular phagocytosis (ADCP) activity of IgG1 antibodies, comprising the steps of: (1) determining the ADCP activity of a reference IgG1 antibody; (2) determining the ADCP activity of a second IgG1 antibody having the same sequence as the reference IgG1 antibody; and (3) altering the ADCP activity of the second IgG1 antibody by increasing or decreasing the amount of core fucose in the second antibody or increasing or decreasing the amount of non-fucosylated species of the second antibody; wherein the ADCP activity of the second antibody after increasing or decreasing the amount of core fucose or increasing or decreasing the amount of non-fucosylated species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

20. 20. The method of claim 19, wherein the reference antibody and the second IgG1 antibody are trastuzumab, and the ADCP activity of the second antibody is increased by decreasing the amount of core fucose in the second antibody or by increasing the amount of non-fucosylated species of the second antibody, and wherein the ADCP activity of the second antibody after increasing the ADCP activity is the same as the reference antibody or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

21. 20. The method of claim 19, wherein the reference antibody and the second IgG1 antibody are trastuzumab, and the ADCP activity of the second trastuzumab antibody is decreased by increasing the amount of core fucose in the second antibody or decreasing the amount of non-fucosylated species of the second antibody, and wherein the ADCP activity of the second antibody after decreasing the ADCP activity is the same as the reference antibody or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

22. 20. The method of claim 19, wherein the reference antibody and the second IgG1 antibody are rituximab, and the ADCP activity of the second rituximab antibody is increased by increasing the amount of core fucose in the second antibody or decreasing the amount of non-fucosylated species of the second antibody, and wherein the ADCP activity of the second antibody after increasing the ADCP activity is the same as the reference antibody or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

23. 20. The method of claim 19, wherein the reference antibody and the second IgG1 antibody are rituximab, and the ADCP activity of the second rituximab antibody is decreased by decreasing the amount of core fucose in the second antibody or by increasing the amount of non-fucosylated species of the second antibody, and wherein the ADCP activity of the second antibody after decreasing the ADCP activity is the same as the reference antibody or is within about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

24. 1. A method of manipulating a specific target antibody-dependent cellular phagocytosis (ADCP) activity of a trastuzumab antibody, comprising the steps of: (1) determining an ADCP activity of the trastuzumab antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the trastuzumab antibody by increasing or decreasing the amount of core fucose in the second antibody, or increasing or decreasing the amount of non-fucosylated species of the second antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of core fucose or increasing or decreasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity.

25. 1. A method of manipulating a specific target antibody-dependent cellular phagocytosis (ADCP) activity of a rituximab antibody, comprising the steps of: (1) determining an ADCP activity of the rituximab antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the rituximab antibody by increasing or decreasing the amount of core fucose in the second antibody or increasing or decreasing the amount of non-fucosylated species of the second antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of core fucose or increasing or decreasing the amount of non-fucosylated species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity.

26. A method for modulating the antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising increasing or decreasing the amount of high mannose in the antibody, or increasing or decreasing the amount of M5 high mannose species in the antibody.

27. A method for increasing antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising decreasing the amount of high mannose in the antibody or decreasing the amount of M5 high mannose species in the antibody.

28. 28. The method of claim 26 or 27, wherein about a 1 percent reduction in high mannose increases ADCP activity by about 1, about 1.2, about 1.31, about 1.5, about 1.7, about 2, about 2.11 or about 2.5 percent.

29. A method for reducing antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising increasing the amount of high mannose in the antibody or increasing the amount of M5 high mannose species in the antibody.

30. 30. The method of claim 26 or 29, wherein about a 1 percent increase in high mannose decreases ADCP activity by about 1, about 1.2, about 1.31, about 1.5, about 1.7, about 2, about 2.11 or about 2.5 percent.

31. 1. A method for matching antibody-dependent cellular phagocytosis (ADCP) activity of IgG1 antibodies, comprising: (1) determining the ADCP activity of a reference IgG1 antibody; (2) determining the ADCP activity of a second IgG1 antibody having the same sequence as the reference IgG1 antibody; and (3) altering the ADCP activity of the second IgG1 antibody by increasing or decreasing the amount of high mannose in the second antibody or increasing or decreasing the amount of M5 high mannose species of the second antibody; wherein the ADCP activity of the second antibody after increasing or decreasing the amount of high mannose or after increasing or decreasing the amount of M5 high mannose species is the same as the reference antibody, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

32. 32. The method of claim 31 , wherein the ADCP activity of the second IgG1 antibody is increased by decreasing the amount of high mannose in the second antibody or by decreasing the amount of M5 high mannose species in the second antibody, and wherein the ADCP activity of the second antibody after increasing the ADCP activity is the same as the reference antibody or is within about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

33. 32. The method of claim 31 , wherein the ADCP activity of the second IgG1 antibody is decreased by increasing the amount of high mannose in the second antibody or by increasing the amount of M5 high mannose species of the second antibody, and wherein the ADCP activity of the second antibody after decreasing the ADCP activity is the same as the reference antibody or is within about 5%, about 10%, about 15%, about 20%, about 25%, about 30% or about 35% of the reference antibody, or is within a range of about 1% to about 35% of the reference antibody.

34. 1. A method for manipulating a specific target antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising the steps of: (1) determining an ADCP activity of an IgG1 antibody; (2) determining a target ADCP activity; and (3) altering the ADCP activity of the IgG1 antibody by increasing or decreasing the amount of high mannose in a second antibody or increasing or decreasing the amount of M5 high mannose species in a second antibody; wherein the ADCP activity of the antibody after increasing or decreasing the amount of high mannose or increasing or decreasing the amount of M5 high mannose species is the same as the target ADCP activity, or is within about 10%, about 15%, about 20%, about 25%, about 30%, or about 35% of the target ADCP activity, or is within a range of about 1% to about 35% of the target ADCP activity.

35. A method for modulating antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising increasing or decreasing (1) the amount of terminal β-galactose in the antibody and / or the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody, (2) the amount of core fucose in the antibody and / or the amount of non-fucosylated species of the antibody, and / or (3) the amount of high mannose in the antibody or the amount of M5 high mannose species of the antibody.

36. A method for increasing antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising: (1) increasing the amount of terminal β-galactose in the antibody, or increasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; (2) decreasing the amount of core fucose in the antibody, or increasing the amount of non-fucosylated species of the antibody; and / or (3) decreasing the amount of high mannose in the antibody, or decreasing the amount of M5 high mannose species of the antibody.

37. 1. A method of decreasing antibody-dependent cellular phagocytosis (ADCP) activity of an IgG1 antibody, comprising: (1) decreasing the amount of terminal β-galactose in the antibody or decreasing the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; (2) increasing the amount of core fucose in the antibody or decreasing the amount of non-fucosylated species of the antibody; and / or (3) increasing the amount of high mannose in the antibody or increasing the amount of M5 high mannose species of the antibody.

38. 38. The method of any one of claims 19 or 31 to 37, wherein the IgG1 antibody and / or the reference antibody is trastuzumab or rituximab.

39. 40. The method of any one of claims 6-9, 19-25, 31-34, or 38, wherein (1) is performed before, after, or simultaneously with (2) and / or (3), or (2) is performed before, after, or simultaneously with (1) and / or (3).

40. 40. The method of any one of claims 1 to 39, wherein the ADCP activity of the antibody is increased or decreased by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, about 150%, about 175%, about 200%, about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or 10-fold, or about 0.5-fold to about 8-fold.

41. (1) the amount of terminal β-galactose in the antibody or the amount of G1, G1a, G1b and / or G2 galactosylated species; (2) the amount of core fucose in the antibody or the amount of non-fucosylated species; and / or (3) the amount of high mannose in the antibody or the amount of M5 high mannose species in the antibody, by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, 41. The method of any one of claims 1 to 40, wherein the amount of the saturation is increased or decreased by about 150%, about 175% or about 200%; or by about 0.5%, about 1%, about 2%, about 3%, about 5%, about 7%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97% or about 98% of the total amount; or by about 0.5% to 98% of the total amount.

42. 42. The method of any one of claims 1 to 41, wherein the amount of (1) terminal β-galactose, (2) G1, G1a, G1b and / or G2 galactosylated species, (3) core fucose, (4) nonfucosylated species, (5) high mannose, and / or (6) M5 high mannose species is a percentage calculated by dividing the amount of terminal β-galactose, G1, G1a, G1b and / or G2 galactosylated species, core fucose, nonfucosylated species, high mannose, or M5 high mannose species by the total amount of all glycans.

43. The method of any one of claims 1 to 42, wherein the ADCP activity is measured or determined using an FcγR reporter gene assay.

44. 44. The method of claim 43, wherein the reporter gene assay comprises Jurkat cells.

45. 45. The method of claim 43 or 44, wherein the reporter gene assay comprises Jurkat cells expressing FcγR receptors, an NFAT response element, and a luciferase reporter gene.

46. The method of any one of claims 43 to 45, wherein the FcγR is FcγRIIa.

47. 47. The method of any one of claims 43 to 46, wherein the assay is an ADCP bioassay kit or other commercially available ADCP assay, or the assay is the Promega ADCP bioassay (catalog number G9901 or G9991).

48. 48. The method of any one of claims 1 to 47, wherein (1) the amount of terminal β-galactose in the antibody, or the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; (2) the amount of core fucose in the antibody, or the amount of non-fucosylated species, and / or (3) the amount of high mannose in the antibody, or the amount of M5 high mannose species of the antibody, is increased or decreased by culturing a cell expressing the antibody in a cell culture medium or under cell culture conditions that adjust (1) the amount of terminal β-galactose in the antibody, or the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; (2) the amount of core fucose in the antibody, or the amount of non-fucosylated species, and / or (3) the amount of high mannose in the antibody, or the amount of M5 high mannose species of the antibody.

49. 49. The method of any one of claims 1 to 48, wherein: (1) the amount of terminal β-galactose in the antibody, or the amount of G1, G1a, G1b and / or G2 galactosylated species of the antibody; (2) the amount of core fucose, or the amount of non-fucosylated species of the antibody; and / or (3) the amount of high mannose in the antibody, or the amount of M5 high mannose species of the antibody, is increased or decreased using chemical means or enzymes.

50. 50. The method of claim 49, wherein the enzyme is selected from the group consisting of EndoS, Endo-S2, Endo-D, Endo-M, endoLL, α-fucosidase, β-(1-4)-galactosidase, Endo-H, β-1,4-galactosyltransferase and PNGase F.

51. 51. The method of any one of claims 48-50, further comprising incubating the antibody with β-1,4-galactosyltransferase for about 10 minutes, about 20 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 9 hours, or for a time period ranging from about 10 minutes to about 9 hours.

52. 52. An IgG1 antibody produced by the method of any one of claims 1 to 51, wherein the antibody has increased or decreased ADCP activity compared to a reference IgG1 antibody having the same antibody sequence as the IgG1 antibody having increased or decreased ADCP activity.

53. 53. The IgG1 antibody of claim 52, wherein the antibody has about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, about 150%, about 175% or about 200%, or about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold or about 10-fold increased ADCP activity compared to the reference antibody, or about 0.5-fold to about 8-fold increased ADCP activity compared to the reference antibody.

54. 53. The IgG1 antibody of claim 52, wherein the antibody has about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 125%, about 150%, about 175% or about 200%, or about 1-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold or about 10-fold decreased ADCP activity compared to the reference antibody, or about 0.5-fold to about 8-fold decreased ADCP activity compared to the reference antibody.

55. The antibody of any one of claims 52 to 54, wherein the IgG1 antibody is trastuzumab or rituximab.

56. The trastuzumab antibody is a. a light chain variable domain comprising: (i) a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:1; (ii) a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:2; and (iii) a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; and b. A heavy chain variable domain comprising: (i) a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; (ii) a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and (iii) a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:

6. Contains or Or, the rituximab antibody is a. a light chain variable domain comprising: (i) a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO: 11; (ii) a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO: 12; and (iii) a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO: 13; and b. A heavy chain variable domain comprising: (i) a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO: 14; (ii) a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO: 15; and (iii) a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:

16. The antibody of any one of claims 1 to 55, comprising:

57. 52. An antibody composition produced by the method of any one of claims 1 to 51.

58. A pharmaceutical composition comprising the antibody composition of any one of claims 52 to 57 and a pharma- ceutically acceptable carrier, diluent or excipient.

Citation Information

Patent Citations

  • Hypergalactosylated anti-her2 antibodies and uses thereof

    JP2016509019A